JPH02229165A - Carbostyril derivative - Google Patents
Carbostyril derivativeInfo
- Publication number
- JPH02229165A JPH02229165A JP5058489A JP5058489A JPH02229165A JP H02229165 A JPH02229165 A JP H02229165A JP 5058489 A JP5058489 A JP 5058489A JP 5058489 A JP5058489 A JP 5058489A JP H02229165 A JPH02229165 A JP H02229165A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- reaction
- lower alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 45
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000003277 amino group Chemical group 0.000 claims abstract description 7
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 4
- 125000005606 carbostyryl group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000005412 pyrazyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 abstract description 81
- 239000002904 solvent Substances 0.000 abstract description 53
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 27
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 4
- 125000004193 piperazinyl group Chemical group 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- ZUGRYLJRHKHZLR-UHFFFAOYSA-N 1h-quinolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2NC(=O)C=CC2=C1 ZUGRYLJRHKHZLR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- -1 Aminopentyl Chemical group 0.000 description 147
- 238000006243 chemical reaction Methods 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- 235000019441 ethanol Nutrition 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 150000001412 amines Chemical class 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 150000007514 bases Chemical class 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 150000001298 alcohols Chemical class 0.000 description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 150000002170 ethers Chemical class 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 235000011121 sodium hydroxide Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000010531 catalytic reduction reaction Methods 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 150000008065 acid anhydrides Chemical class 0.000 description 8
- 239000002798 polar solvent Substances 0.000 description 8
- 235000011118 potassium hydroxide Nutrition 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 150000008282 halocarbons Chemical class 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 235000011181 potassium carbonates Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910003446 platinum oxide Inorganic materials 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 239000003377 acid catalyst Chemical class 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003721 gunpowder Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- ZWRCXARKVKXNDP-UHFFFAOYSA-N 1-(2-aminophenyl)-4-chlorobutan-1-one Chemical compound NC1=CC=CC=C1C(=O)CCCCl ZWRCXARKVKXNDP-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 150000003948 formamides Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKDOTCFNLHHKOF-FGRDZWBJSA-N (z)-1-chloroprop-1-ene;(z)-1,2-dichloroethene Chemical group C\C=C/Cl.Cl\C=C/Cl UKDOTCFNLHHKOF-FGRDZWBJSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- XGHQPUKUQIJNAP-UHFFFAOYSA-N 2-chloro-1,3,5-trimethylbenzene;sulfur dioxide Chemical compound O=S=O.CC1=CC(C)=C(Cl)C(C)=C1 XGHQPUKUQIJNAP-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- JSGVZVOGOQILFM-UHFFFAOYSA-N 3-methoxy-1-butanol Chemical compound COC(C)CCO JSGVZVOGOQILFM-UHFFFAOYSA-N 0.000 description 1
- BONJIDVJFLTCSE-UHFFFAOYSA-N 3-methoxyprop-2-enoyl chloride Chemical compound COC=CC(Cl)=O BONJIDVJFLTCSE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QPQGTZMAQRXCJW-UHFFFAOYSA-N [chloro(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(Cl)C1=CC=CC=C1 QPQGTZMAQRXCJW-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- PQFZWNNSXMOCAL-UHFFFAOYSA-N acetyl acetate;methylsulfinylmethane Chemical compound CS(C)=O.CC(=O)OC(C)=O PQFZWNNSXMOCAL-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- SISAYUDTHCIGLM-UHFFFAOYSA-N bromine dioxide Inorganic materials O=Br=O SISAYUDTHCIGLM-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- XCPXPFNKTCFWTA-UHFFFAOYSA-N ethyl carbonobromidate Chemical compound CCOC(Br)=O XCPXPFNKTCFWTA-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- QXUAFCKBYYPTPQ-ZWKAXHIPSA-L magnesium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QXUAFCKBYYPTPQ-ZWKAXHIPSA-L 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QQHNGZNHRRLNKI-UHFFFAOYSA-N methyl carbonobromidate Chemical compound COC(Br)=O QQHNGZNHRRLNKI-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- DDCYYCUMAFYDDU-UHFFFAOYSA-N methyl thiohypochlorite Chemical compound CSCl DDCYYCUMAFYDDU-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QPNOPWWAMGQISP-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;methylsulfinylmethane Chemical compound CS(C)=O.C1CCCCC1N=C=NC1CCCCC1 QPNOPWWAMGQISP-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- RPPXBFUXDUGSMF-UHFFFAOYSA-N n-bromoacetamide;sulfur dioxide Chemical compound O=S=O.CC(=O)NBr RPPXBFUXDUGSMF-UHFFFAOYSA-N 0.000 description 1
- OMPVAQNHVHNJEC-UHFFFAOYSA-N n-diaminophosphorylaniline Chemical compound NP(N)(=O)NC1=CC=CC=C1 OMPVAQNHVHNJEC-UHFFFAOYSA-N 0.000 description 1
- FJLHLDBEZKTSOK-UHFFFAOYSA-N n-ethyl-n-methylformamide Chemical compound CCN(C)C=O FJLHLDBEZKTSOK-UHFFFAOYSA-N 0.000 description 1
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- WEQHQGJDZLDFID-UHFFFAOYSA-J thorium(iv) chloride Chemical compound Cl[Th](Cl)(Cl)Cl WEQHQGJDZLDFID-UHFFFAOYSA-J 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、新規なカルボスチリル誘導体に関する。[Detailed description of the invention] Industrial applications The present invention relates to novel carbostyryl derivatives.
発明の開示
本発明のカルボスチリル誘導体は文献未記載の新規化合
物であり、下記一般式(1)で表わされる。DISCLOSURE OF THE INVENTION The carbostyril derivative of the present invention is a novel compound that has not been described in any literature, and is represented by the following general formula (1).
一般式
[式中Rは、水素原子、低級アルキル基、低級は同−又
は異なって、水素原子又は低級アルキル基を示す。また
R3a及びR3bは結合する窒素原子と共に、窒素原子
又は酸素原子を介し又は介さず5〜6員環の飽和複素環
を形成してもよい。)を有する低級アルキル基又はハロ
ゲン原子置換低級アルキル基を示す。Aは基
CH−(R2は水酸基、低級アルコキシ基又は低級アル
カノイルオキシ基を示す。)、基−CH=CH−1又は
基−C−を示す。0は1又は2を示す。Bは低級アルキ
レン基を示す。R1は、置換基として、低級アルキル基
、低級アルコキシ基及び置換基として低級アルキル基を
有することのあるアミノ基からなる群より選ばれた基を
1〜3個有することのあるピリジル基、置換基として低
級アルキル基を有することのあるピペリジニル基、ピラ
ジル基又は基
/R3
−(Co)n−N、 (R”及びR4は同−又は
異なって、水素原子又は低級アルキル基を示す。またR
3及びR4は結合する窒素原子と共に窒素原子又は酸素
原子を介し又は介さず5〜6員環の飽和複素環を形成し
てもよい。該複素環には置換基として低級アルキル基が
置換してもよい。)を示す。4.m及びnはそれぞれ0
又は1を示す。但し、1十mは0であってはならない。General Formula [In the formula, R is a hydrogen atom or a lower alkyl group, and lower is the same or different and represents a hydrogen atom or a lower alkyl group. Further, R3a and R3b may form a 5- to 6-membered saturated heterocycle with or without a nitrogen atom or an oxygen atom, together with the nitrogen atom to which they are bonded. ) or a halogen atom-substituted lower alkyl group. A represents a group CH- (R2 represents a hydroxyl group, a lower alkoxy group or a lower alkanoyloxy group), a group -CH=CH-1 or a group -C-. 0 indicates 1 or 2. B represents a lower alkylene group. R1 is a pyridyl group or substituent that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group, and an amino group that may have a lower alkyl group as a substituent; piperidinyl group, pyrazyl group or group which may have a lower alkyl group /R3 -(Co)n-N, (R" and R4 are the same or different and represent a hydrogen atom or a lower alkyl group. Also, R
3 and R4 may form a 5- to 6-membered saturated heterocycle together with the nitrogen atom to which they are bonded, with or without a nitrogen or oxygen atom. The heterocycle may be substituted with a lower alkyl group as a substituent. ) is shown. 4. m and n are each 0
Or indicates 1. However, 10m must not be 0.
更に、AがC−を示すとき、mは1を示すものとする。Furthermore, when A represents C-, m shall represent 1.
カルボスチリル骨格の3.4位の結合は、重結合又は二
重結合を示す。]
で表わされるカルボスチリル誘導体及びその塩。The bond at position 3.4 of the carbostyryl skeleton represents a double bond or a double bond. ] A carbostyryl derivative represented by these and its salt.
上記一般式(1)で表わされるカルボスチリル誘導体及
びその塩は、抗不整脈作用を有している。The carbostyril derivative represented by the above general formula (1) and its salt have an antiarrhythmic effect.
上記化合物は、特に心筋の収縮力には殆んど影響を及ぼ
さず、虚血時等に生じる刺激生成異常を抑制するという
特徴を有している。The above-mentioned compound has the characteristic that it has almost no effect on the contractile force of the myocardium, and suppresses stimulation generation abnormalities that occur during ischemia and the like.
本明細書において、R5R1、A及びBで示される各基
は、より具体的にはそれぞれ以下の通りである。In this specification, each group represented by R5R1, A and B is more specifically as follows.
低級アルキル基としては、例えば、メチル、エチル、プ
ロピル、イソプロピル、ブチル、tertブチル、ペン
チル、ヘキシル基等の炭素数1〜6の直鎖又は分枝鎖状
アルキル基を挙げることかできる。Examples of the lower alkyl group include straight-chain or branched alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, and hexyl groups.
は、例えばアミノメチル、1−アミノエチル、2アミノ
エチル、3−アミノプロピル、4−アミノブチル、5−
アミノペンチル、6−アミノヘキシル、1,1−ジメチ
ル−2−アミノエチル、2メチル−3−アミノプロピル
、メチルアミノメチル、エチルアミノメチル、プロピル
アミノメチル、イソプロピルアミノメチル、ブチルアミ
ノメチル、tert−ブチルアミノメチル、ペンチルア
ミノメチル、ヘキシルアミノメチル、ジメチルアミノメ
チル、ジエチルアミノメチル、ジプロピルアミノメチル
、ジブチルアミノメチル、ジエチルアミノエチル、ジエ
チルアミノエチル、N−メチル−N−エチルアミノメチ
ル、N−エチル−Nプロピルアミノメチル、N−メチル
−N−ブチルアミノメチル、N−メチル−N−へキシル
アミノメチル、2−メチルアミノエチル、1−エチルア
ミノエチル、3−プロピルアミノプロピル、4ブチルア
ミノブチル、1,1−ジメチル−2ペンチルアミノエチ
ル、5−へキシルアミノペンチル、6−シメチルアミノ
ヘキシル、2−ジエチルアミノエチル、1−(N−メチ
ル−N−へキシルアミノ)エチル、3−ジヘキシルアミ
ノプロピル、4−ジブチルアミノブチル、2−(N−メ
チル−N−ペンチルアミノ)エチル、3−(1−ピロリ
ジニル)プロピル、(1−ピペラジニル)メチル、2−
モルホリノエチル、1−(1−ピペリジニル)エチル、
4− (1−ピロリジニル)ブチル、5−(1−ピペラ
ジニル)ペンチル、6(1−ピリジニル)ヘキシル基等
の、基なって、水素原子又は炭素数1〜6の直鎖又は分
枝鎖状アルキル基を示す。またR3a′及びR3b′は
、結合する窒素原子と共に、窒素原子又は酸素原子を介
し又は介さずピロリジニル、ピペラジニル、ピペリジニ
ル、モルホリノ等の5〜6員環の飽和の複素環を形成し
てもよい。)を有する炭素数1〜6の直鎖又は分枝鎖状
アルキル基を挙げることができる。is, for example, aminomethyl, 1-aminoethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminobutyl.
Aminopentyl, 6-aminohexyl, 1,1-dimethyl-2-aminoethyl, 2methyl-3-aminopropyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, butylaminomethyl, tert-butyl Aminomethyl, pentylaminomethyl, hexylaminomethyl, dimethylaminomethyl, diethylaminomethyl, dipropylaminomethyl, dibutylaminomethyl, diethylaminoethyl, diethylaminoethyl, N-methyl-N-ethylaminomethyl, N-ethyl-N-propylamino Methyl, N-methyl-N-butylaminomethyl, N-methyl-N-hexylaminomethyl, 2-methylaminoethyl, 1-ethylaminoethyl, 3-propylaminopropyl, 4-butylaminobutyl, 1,1- Dimethyl-2pentylaminoethyl, 5-hexylaminopentyl, 6-dimethylaminohexyl, 2-diethylaminoethyl, 1-(N-methyl-N-hexylamino)ethyl, 3-dihexylaminopropyl, 4-dibutylamino Butyl, 2-(N-methyl-N-pentylamino)ethyl, 3-(1-pyrrolidinyl)propyl, (1-piperazinyl)methyl, 2-
Morpholinoethyl, 1-(1-piperidinyl)ethyl,
A hydrogen atom or a straight or branched alkyl group having 1 to 6 carbon atoms, such as 4-(1-pyrrolidinyl)butyl, 5-(1-piperazinyl)pentyl, 6(1-pyridinyl)hexyl group, etc. Indicates the group. Further, R3a' and R3b' together with the nitrogen atom to which they are bonded may form a 5- to 6-membered saturated heterocycle such as pyrrolidinyl, piperazinyl, piperidinyl, morpholino, etc., with or without a nitrogen or oxygen atom. ) and a C1-C6 straight or branched alkyl group.
低級アルコキシ基としては11例えばメトキシ、エトキ
シ、プロポキシ、イソプロポキシ、ブトキシ、tert
−ブトキシ、ペンチルオキシ、ヘキシルオキシ基等の炭
素数1〜6の直鎖又は分枝鎖状アルコキシ基を挙げるこ
とができる。Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert
- C1-C6 straight or branched alkoxy groups such as -butoxy, pentyloxy, hexyloxy groups and the like can be mentioned.
低級アルカイツルオキシ基としては、例えばポルミルオ
キシ、アセチルオキシ、プロピオニルオキシ、ブチリル
オキシ、イソブチリルオキシ、ペンタノイルオキシ、t
ert−ブチルカルボニルオキシ、ヘキザノイルオキシ
基等の炭素数1〜6の直鎖又は分枝鎖状アルカノイルオ
キシ基を挙げることができる。Examples of the lower alkyloxy group include polmyloxy, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pentanoyloxy, t
Examples include straight-chain or branched alkanoyloxy groups having 1 to 6 carbon atoms, such as ert-butylcarbonyloxy and hexanoyloxy groups.
低級アルキレン基としては、メチレン、エチレン、トリ
メチレン、2−メチルトリメチレン、2゜2−ジメチル
トリメチレン、1−メチルトリメチレン、メチルメチレ
ン、エチルメチレン、テトラメチレン、ペンタメチレン
、ヘキサメチレン基等の炭素数1〜6の直鎖又は分枝鎖
状アルキレン基を挙げることができる。Examples of lower alkylene groups include carbon groups such as methylene, ethylene, trimethylene, 2-methyltrimethylene, 2゜2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, tetramethylene, pentamethylene, and hexamethylene groups. Mention may be made of 1 to 6 linear or branched alkylene groups.
置換基として低級アルキル基を有することのあるアミノ
基としては、例えばアミノ、メチルアミノ、エチルアミ
ノ、プロピルアミノ、イソプロピルアミノ、ブチルアミ
ノ、tert−ブチルアミノ、ペンチルアミノ、ヘキシ
ルアミノ、ジメチルアミノ、ジエチルアミノ、ジプロピ
ルアミノ、ジブチルアミノ、ジエチルアミノ、ジエチル
アミノ、N−メチル−N−エチルアミノ、N−エチル−
Nプロピルアミノ、N−メチル−N−ブチルアミノ、N
−メチル−N−ヘキシルアミノ基等の炭素数1〜6の直
鎖又は分枝鎖状アルキル基が1〜2個置換することのあ
るアミノ基を挙げることができる。Examples of amino groups that may have a lower alkyl group as a substituent include amino, methylamino, ethylamino, propylamino, isopropylamino, butylamino, tert-butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, Dipropylamino, dibutylamino, diethylamino, diethylamino, N-methyl-N-ethylamino, N-ethyl-
N-propylamino, N-methyl-N-butylamino, N
-Methyl-N-hexylamino group and other amino groups that may be substituted with one or two straight or branched alkyl groups having 1 to 6 carbon atoms can be mentioned.
置換基として、低級アルキル基、低級アルコキシ基及び
置換基として低級アルキル基を有することのあるアミノ
基からなる群より選ばれた基を1〜3個有することのあ
るピリジル基としては、例えば2−ピリジル、3−ピリ
ジル、4−ピリジル、6−シメチルアミノー2−ピリジ
ル、5−メトキシ−2−ピリジル、4−メトキシ−2−
ピリジル、6−メドキシー2−ピリジル、3−メチル−
2−ピリジル、4−メチル−2−ピリジル、6−メチル
−2−ピリジル、1−メチル−ピリジニウム、4−メチ
ル−6−シメチルアミノー2−ピリジル、2−エチル−
3−ピリジル、3−プロピル−4ピリジル、4−ブチル
−2−ピリジル、3−ペンチル−2−ピリジル、4−へ
キシル−3−ピリジル、2−エトキシ−3−ピリジル、
3−プロポキシ−4−ピリジル、4−ブトキシ−2−ピ
リジル、3−ペンチルオキシ−2−ピリジル、4−へキ
シルオキシ−3−ピリジル、4−アミノ−2−ピリジル
、3−エチルアミノ−2−ピリジル、4−プロピルアミ
ノ−3−ピリジル、2−ペンチルアミノ−4−ピリジル
、4−へキシルアミノ−2−ピリジル、6−ダニチルア
ミノ−2−ピリジル、4−ジペンチルアミノー2−ピリ
ジル、6−(N−メルチ−N−エチルアミノ)−2−ピ
リジル、3゜4−ジメチル−2−ピリジル、3,4.6
−4リメチル−2−ピリジル、3,4.5−)リフトキ
シ−2−ピリジル、4.6−シメトキシー2−ピリジル
、4−エチル−6−シプロピルアミノー2−ピリジル基
等の、置換基として、炭素数1〜6の直鎖又は分枝鎖状
アルキル基、炭素数1〜6の直鎖又は分枝鎖状アルコキ
シ基及び、炭素数1〜6の直鎖又は分枝鎖状アルキル基
が1〜2個置換することのあるアミノ基からなる群より
選はれた基を1〜3個有することあるピリジル基を挙げ
ることができる。As a pyridyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group, and an amino group that may have a lower alkyl group as a substituent, for example, 2- Pyridyl, 3-pyridyl, 4-pyridyl, 6-dimethylamino-2-pyridyl, 5-methoxy-2-pyridyl, 4-methoxy-2-
Pyridyl, 6-medoxy-2-pyridyl, 3-methyl-
2-pyridyl, 4-methyl-2-pyridyl, 6-methyl-2-pyridyl, 1-methyl-pyridinium, 4-methyl-6-dimethylamino-2-pyridyl, 2-ethyl-
3-pyridyl, 3-propyl-4pyridyl, 4-butyl-2-pyridyl, 3-pentyl-2-pyridyl, 4-hexyl-3-pyridyl, 2-ethoxy-3-pyridyl,
3-propoxy-4-pyridyl, 4-butoxy-2-pyridyl, 3-pentyloxy-2-pyridyl, 4-hexyloxy-3-pyridyl, 4-amino-2-pyridyl, 3-ethylamino-2-pyridyl , 4-propylamino-3-pyridyl, 2-pentylamino-4-pyridyl, 4-hexylamino-2-pyridyl, 6-danitylamino-2-pyridyl, 4-dipentylamino-2-pyridyl, 6-(N- Merti-N-ethylamino)-2-pyridyl, 3゜4-dimethyl-2-pyridyl, 3,4.6
-4-limethyl-2-pyridyl, 3,4.5-)liftoxy-2-pyridyl, 4,6-simethoxy-2-pyridyl, 4-ethyl-6-cypropylamino-2-pyridyl, etc. as a substituent , a straight chain or branched alkyl group having 1 to 6 carbon atoms, a straight chain or branched alkyl group having 1 to 6 carbon atoms, and a straight chain or branched alkyl group having 1 to 6 carbon atoms. Examples include pyridyl groups which may have 1 to 3 groups selected from the group consisting of amino groups which may be substituted with 1 to 2 atoms.
置換基として低級アルキル基を有することのあるピペリ
ジニル基としては、例えば2−ピペリジニル、3−ピペ
リジニル、4−ピペリジニル、1メチル−2−ピペリジ
ニル、1−エチル−2ピペリジニル、1−プロピル−2
−ピペリジニル、1−ブチル−2−ピペリジニル、1−
ペンチル−2−ピペリジニル、6−メチル−2−ピペリ
ジニル、5−メチル−2−ピペリジニル、1−へキシル
−2−ピペリジニル、2−メチル−3−ピペリジニル、
3−メチル−4−ピペリジニル、1−エチル−3−ピペ
リジニル、1−ブチル−4−ピペリジニル、1,6−シ
メチルー2−ピペリジニル、1.3.4−トリメチル−
2−ピペリジニル基等の、置換基として炭素数1〜6の
直鎖又は分枝鎖状アルキル基を1〜3個有することのあ
る(23−又は4−)ピペリジニル基を挙げることがで
きる。Examples of the piperidinyl group that may have a lower alkyl group as a substituent include 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-methyl-2-piperidinyl, 1-ethyl-2-piperidinyl, 1-propyl-2
-piperidinyl, 1-butyl-2-piperidinyl, 1-
Pentyl-2-piperidinyl, 6-methyl-2-piperidinyl, 5-methyl-2-piperidinyl, 1-hexyl-2-piperidinyl, 2-methyl-3-piperidinyl,
3-Methyl-4-piperidinyl, 1-ethyl-3-piperidinyl, 1-butyl-4-piperidinyl, 1,6-cymethyl-2-piperidinyl, 1.3.4-trimethyl-
Examples include (23- or 4-)piperidinyl groups, such as 2-piperidinyl groups, which may have 1 to 3 linear or branched alkyl groups having 1 to 6 carbon atoms as substituents.
R3及びR4が結合する窒素原子と共に、窒素原子又は
酸素原子を介し又は介することなく形成する5員又は6
員の飽和複素環基としては、例えばピペラジニル基、ピ
ペリジニル基、モルホリノ基、ピロリジニル基等を挙げ
ることができる。A 5-membered or 6-membered compound formed with the nitrogen atom to which R3 and R4 are bonded, with or without a nitrogen atom or an oxygen atom.
Examples of the member saturated heterocyclic group include a piperazinyl group, a piperidinyl group, a morpholino group, and a pyrrolidinyl group.
低級アルキル基が置換した上記複素環基としては、例え
ば4−メチル−1−ピペリジニル、2メチル−1−モル
ホリノ、2−メチル−1−ピロリジニル、4−エチル−
1−ピペラジニル、3プロピル−1−モルホリノ、4−
イソプロピル1−ピペリジニル、3−ブチル−1−ピロ
リジニル、4−tert−ブチル−1−ピペラジニル、
4ペンチル−1−ピペリジニル、3−へキシル−1モル
ホリノ、3.4−ジメチル−1−ピペラジニル、2,4
−ジメチル−1−ピペラジニル、2゜6−シメチルー1
−ピペリジニル、3,4.5−トリメチル−1−ピペラ
ジニル基等の、炭素数1〜6の直鎖又は分枝鎖アルキル
基が1〜3個置換した複素環基を挙げることができる。Examples of the above heterocyclic group substituted with a lower alkyl group include 4-methyl-1-piperidinyl, 2methyl-1-morpholino, 2-methyl-1-pyrrolidinyl, 4-ethyl-
1-piperazinyl, 3propyl-1-morpholino, 4-
Isopropyl 1-piperidinyl, 3-butyl-1-pyrrolidinyl, 4-tert-butyl-1-piperazinyl,
4pentyl-1-piperidinyl, 3-hexyl-1morpholino, 3,4-dimethyl-1-piperazinyl, 2,4
-dimethyl-1-piperazinyl, 2゜6-cymethyl-1
-Piperidinyl, 3,4.5-trimethyl-1-piperazinyl, and other heterocyclic groups substituted with 1 to 3 straight or branched alkyl groups having 1 to 6 carbon atoms.
ハロゲン原子置換低級アルキル基としては、例えば、ト
リフルオロメチル、トリクロロメチル、クロロメチル、
ブロモメチル、フルオロメチル、ヨードメチル、ジフル
オロメチル、ジブロモメチル、2−クロロエチル、2.
2.2−トリフルオロエチル、2,2.2−トリクロロ
エチル、3クロロプロピル、2,3−ジクロロプロピル
、4゜4.4−トリクロロブチル、4−フルオロブチル
、5−クロロペンチル、3−クロロ−2−メチルプロピ
ル、5−ブロモヘキシル、5,6−ジクロロヘキシル基
等の、ハロゲン原子を1〜3個有する炭素数1〜6の直
鎖又は分枝鎖状アルキル基を挙げることができる。Examples of the halogen-substituted lower alkyl group include trifluoromethyl, trichloromethyl, chloromethyl,
Bromomethyl, fluoromethyl, iodomethyl, difluoromethyl, dibromomethyl, 2-chloroethyl, 2.
2.2-trifluoroethyl, 2,2.2-trichloroethyl, 3chloropropyl, 2,3-dichloropropyl, 4゜4.4-trichlorobutyl, 4-fluorobutyl, 5-chloropentyl, 3-chloro Examples include straight-chain or branched alkyl groups having 1 to 6 carbon atoms and having 1 to 3 halogen atoms, such as -2-methylpropyl, 5-bromohexyl, and 5,6-dichlorohexyl.
上記−設入(1)で表わされるカルボスチリル誘導体は
、種々の方法により製造され得るか、その−例を示せば
下記反応式で示される方法に従い容易に製造される。The carbostyryl derivative represented by the above-mentioned (1) can be produced by various methods, and for example, it can be easily produced according to the method shown in the following reaction formula.
[反応式−1]
H
(1a)
[式中R,R’ 、B、m及びカルボスチリル骨格の3
,4位の結合は前記に同じ。Mはリチウム又はMgX
(Xはハロゲン原子を示す)を示す。[Reaction formula-1] H (1a) [In the formula, R, R', B, m and 3 of the carbostyril skeleton
, the bond at position 4 is the same as above. M is lithium or MgX
(X represents a halogen atom).
]
一般式(2)の化合物と一般式(3)の化合物との反応
は、適当な溶媒中にて行なわれる。ここで使用される溶
媒としては、例えばジオキサン、テトラヒドロフラン、
ジエチルエーテル等のエーテル類、ベンゼン、トルエン
等の芳香族炭化水素類、ペンタン、ヘキサン、ヘプタン
、シクロヘキサン等の飽和炭化水素類又はこれらの混合
溶媒を例示できる。化合物(3)は、化合物(2)に対
して通常少くとも等モル、好ましくは等モル−5倍モル
量程度使用するのがよい。上記反応は、通常−50〜1
00℃、好ましくは一50°C〜70°C付近にて好適
に進行し、一般に0.5〜5時間程度で完結する。] The reaction between the compound of general formula (2) and the compound of general formula (3) is carried out in a suitable solvent. Examples of the solvent used here include dioxane, tetrahydrofuran,
Examples include ethers such as diethyl ether, aromatic hydrocarbons such as benzene and toluene, saturated hydrocarbons such as pentane, hexane, heptane, and cyclohexane, and mixed solvents thereof. Compound (3) is usually used in an amount of at least equimolar, preferably equimolar to 5 times the molar amount of compound (2). The above reaction is usually -50 to 1
The process progresses suitably at 00°C, preferably around -50°C to 70°C, and is generally completed in about 0.5 to 5 hours.
[反応式−2]
[式中、R,R3、R4及びカルボスチリル骨格の3,
4位の結合は前記に同じ。Xはハロゲン原子を示す。]
ハロゲン原子としては、例えば、塩素、臭素、沃素、フ
ッ素原子等を挙げることができる。[Reaction formula-2] [In the formula, R, R3, R4 and 3 of the carbostyryl skeleton,
The bond at position 4 is the same as above. X represents a halogen atom. ] Examples of the halogen atom include chlorine, bromine, iodine, and fluorine atoms.
化合物(2)と化合物(4)の反応は、塩基性化合物の
存在下、適当な溶媒中にて行なわれる。The reaction between compound (2) and compound (4) is carried out in a suitable solvent in the presence of a basic compound.
ここで使用される塩基性化合物としては、金属ナトリウ
ム、金属カリウム、水素化ナトリウム、ナトリウムアミ
ド、水酸化ナトリウム、水酸化カリウム、炭酸ナトリウ
ム、炭酸カリウム、炭酸水素ナトリウム等の無機塩基、
ナトリウムメチラート、ナトリウムエチラート、カリウ
ムt−ブトキシド等の金属アルコラード類、メチルリチ
ウム、nブチルリチウム、フェニルリチウム、リチウム
ジイソプロピルアミド等のアルキル及びアリールリチウ
ム又はリチウムアミド類、ピリジン、ピペリジン、キノ
リン、トリエチルアミン、N、N−ジメチルアニリン等
の有機塩基等を例示できる。溶媒としては、反応に影響
を与えないものであればいずれも使用できるが、例えは
メタノール、エタノール、イソプロパツール等のアルコ
ール類、ジエチルエーテル、ジオキサン、テトラヒドロ
フラン、モノグライム、ジグライム等のエーテル類、ベ
ンゼン、トルエン、キシレン等の芳香族炭化水素類、ヘ
キサン、ヘプタン、シクロヘキサン等の脂肪族炭化水素
類、ピリジン、N、N−ジメチルアニリン等のアミン類
、N、 N−ジメチルホルムアミド、ジメチルスルホキ
シド、ヘキサメチルリン酸トリアミド等の極性溶媒等が
挙げられる。反応温度は、通常〜100°C1好ましく
は0〜80°C付近である。反応は、0.5〜5時間程
度で終了する。化合物(4)の使用量は、化合物(2)
に対して、通常1〜10倍モル、好ましくは1〜6倍モ
ル程度とするのがよい。The basic compounds used here include inorganic bases such as sodium metal, potassium metal, sodium hydride, sodium amide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydrogen carbonate;
Metal alcoholades such as sodium methylate, sodium ethylate, potassium t-butoxide, alkyl and aryl lithium or lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide, pyridine, piperidine, quinoline, triethylamine, Examples include organic bases such as N,N-dimethylaniline. Any solvent can be used as long as it does not affect the reaction, but examples include alcohols such as methanol, ethanol and isopropanol, ethers such as diethyl ether, dioxane, tetrahydrofuran, monoglyme and diglyme, and benzene. , aromatic hydrocarbons such as toluene and xylene, aliphatic hydrocarbons such as hexane, heptane and cyclohexane, amines such as pyridine, N,N-dimethylaniline, N,N-dimethylformamide, dimethylsulfoxide, hexamethyl Examples include polar solvents such as phosphoric acid triamide. The reaction temperature is usually around 100°C, preferably around 0-80°C. The reaction is completed in about 0.5 to 5 hours. The amount of compound (4) used is the same as that of compound (2).
The amount is usually 1 to 10 times, preferably 1 to 6 times, by mole.
化合物(5)と化合物(6)の反応は、適当な溶媒中又
は非存在下、好ましくは溶媒中、塩基性化合物の存在下
行なわれる。ここで使用される溶媒としては、例えば、
ジオキサン、テトラヒドロフラン、エチレングリコール
ジメチルエーテル類等のエーテル類、ベンゼン、トルエ
ン、キシレン等の芳香族炭化水素類、メタノール、エタ
ノール、イソプロパツール等の低級アルコール類、アセ
トニトリル、ジメチルホルムアミド、ジメチルスルホキ
シド、ヘキサメチルリン酸トリアミド等の非プロトン性
極性溶媒等を例示できる。塩基性化合物としては、化合
物(6)を過剰に用いることによっても行うことができ
るが、例えば炭酸カリウム、炭酸ナトリウム、水酸化ナ
トリウム、水酸化カリウム、炭酸水素ナトリウム、ナト
リウムアミド等の無機塩基、トリエチルアミン、トリプ
ロピルアミン、ピリジン、キノリン等の有機塩基等を例
示できる。The reaction between compound (5) and compound (6) is carried out in a suitable solvent or in the absence, preferably in a solvent and in the presence of a basic compound. Examples of the solvent used here include, for example,
Ethers such as dioxane, tetrahydrofuran, and ethylene glycol dimethyl ethers, aromatic hydrocarbons such as benzene, toluene, and xylene, lower alcohols such as methanol, ethanol, and isopropanol, acetonitrile, dimethylformamide, dimethyl sulfoxide, and hexamethyl phosphorus. Examples include aprotic polar solvents such as acid triamides. As the basic compound, the compound (6) can be used in excess, but for example, inorganic bases such as potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium amide, triethylamine, etc. , tripropylamine, pyridine, quinoline, and other organic bases.
反応は、通常室温〜200°c1好ましくは室温〜12
0℃付近の温度下に行なわれ、通常1〜24時間程度に
て終了する。The reaction is usually carried out at room temperature to 200°C, preferably room temperature to 12
The process is carried out at a temperature around 0°C and usually takes about 1 to 24 hours to complete.
化合物(6)の使用量は、化合物(5)に対して通常少
なくとも等モル、好ましくは等モル−大過剰量とするの
がよい。The amount of compound (6) to be used is usually at least equimolar, preferably equimolar - large excess to compound (5).
[反応式−3]
H
(IC)
(1d)
(1a)
OR”
(1f)
(1e)
[式中、RSR’ 、B、m、X及びカルボスチリル骨
格の3.4位の結合は前記に同じ。R5は低級アルカノ
イル基を示す。R6は低級アルコキシ基を示す。]
化合物(1a)と化合物(7a)又は(7b)との反応
は、無溶媒又は適当な溶媒中、塩基性化合物の存在下も
しくは非存在下、好ましくは存在下行なわれる。[Reaction formula-3] H (IC) (1d) (1a) OR" (1f) (1e) [In the formula, RSR', B, m, X and the bond at position 3.4 of the carbostyril skeleton are as described above Same. R5 represents a lower alkanoyl group. R6 represents a lower alkoxy group.] The reaction between compound (1a) and compound (7a) or (7b) can be carried out without a solvent or in a suitable solvent in the presence of a basic compound. It is carried out in the presence or absence, preferably in the presence.
上記反応において適当な溶媒としては、例えば前述した
芳香族炭化水素類、メタノール、エタノール、プロパツ
ール等の低級アルコール類、ジメチルホルムアミド、ジ
メチルスルホキシド等の他、クロロホルム、塩化メチレ
ン等のハロゲン化炭化水素類、アセトン、ピリジン等を
使用できる。塩基性化合物としては、例えばトリエチル
アミン、ピリジン等の第三級アミン類、水酸化ナトリウ
ム、水酸化カリウム、水素化ナトリウム等を例示できる
。また上記反応は、酢酸等の溶媒中、硫酸等の鉱酸の存
在下に実施することもできる。Suitable solvents for the above reaction include, for example, the aromatic hydrocarbons mentioned above, lower alcohols such as methanol, ethanol and propatool, dimethylformamide and dimethyl sulfoxide, as well as halogenated hydrocarbons such as chloroform and methylene chloride. , acetone, pyridine, etc. can be used. Examples of the basic compound include tertiary amines such as triethylamine and pyridine, sodium hydroxide, potassium hydroxide, and sodium hydride. The above reaction can also be carried out in a solvent such as acetic acid in the presence of a mineral acid such as sulfuric acid.
化合物(7a)又は(7b)の使用割合は、化合物(1
a)に対して等モル量以上、好ましくは等モル−10倍
モル量程度とすればよく、反応は通常0〜200°C程
度、好ましくは0〜150℃程度の温度下に、0.5〜
15時間程度で完結する。The usage ratio of compound (7a) or (7b) is
It is sufficient to use an equimolar amount or more, preferably about an equimolar to 10 times the molar amount of a), and the reaction is usually carried out at a temperature of about 0 to 200°C, preferably about 0 to 150°C. ~
It will be completed in about 15 hours.
化合物(IC)を化合物(1d)に導く反応は、適当な
溶媒中、接触還元触媒を用いて化合物(IC)を還元す
ることにより行われる。使用される溶媒としては、例え
ば水、酢酸、メタノール、エタノール、イソプロパツー
ル等のアルコール類、ヘキサン、シクロヘキサン等の炭
化水素類、ジオキサン、テトラヒドロフラン、ジエチル
エーテル、ジエチレングリコールジメチルエーテル等の
エーテル類、酢酸エチル、酢酸メチル等のエステル類、
N、N−ジメチルホルムアミド等の非プロトン性極性溶
媒等が挙げられる。使用される接触還元触媒としては、
例えばパラジウム、パラジウム−黒、パラジウム−炭素
、白金、酸化白金、亜クロム酸銅、ラネーニッケル等が
挙げられる。触媒は、出発原料に対して一般に0.02
〜1倍量程度用いるのがよい。反応温度は、通常−20
〜150°C付近、好ましくは0〜100°C付近、水
素圧は通常1〜10気圧とするのがよく、該反応は一般
に0.5〜10時間程度にて終了する。The reaction of leading compound (IC) to compound (1d) is carried out by reducing compound (IC) using a catalytic reduction catalyst in a suitable solvent. Examples of solvents used include water, alcohols such as acetic acid, methanol, ethanol, and isopropanol; hydrocarbons such as hexane and cyclohexane; ethers such as dioxane, tetrahydrofuran, diethyl ether, and diethylene glycol dimethyl ether; ethyl acetate; Esters such as methyl acetate,
Examples include aprotic polar solvents such as N,N-dimethylformamide. The catalytic reduction catalyst used is
Examples include palladium, palladium-black, palladium-carbon, platinum, platinum oxide, copper chromite, and Raney nickel. The catalyst is generally 0.02
It is best to use about 1 times the amount. The reaction temperature is usually -20
The temperature is preferably around 150°C, preferably around 0-100°C, the hydrogen pressure is usually 1-10 atm, and the reaction is generally completed in about 0.5-10 hours.
−設入(1a)の化合物と一般式(8)の化合物との反
応は、一般に適当な不活性溶媒中、塩基性化合物の存在
下又は不存在下にて行われる。用いられる不活性溶媒と
しては、例えばベンゼン、トルエン、キシレン等の芳香
族炭化水素類、テトラヒドロフラン、ジオキサン、ジエ
チレングリコールジメチルエーテル等のエーテル類、メ
タノール、エタノール、イソプロパツール、ブタノール
等の低級アルコール類、ヘプタン、ヘキサン、シクロヘ
キサン等の脂肪族炭化水素類、酢酸、酢酸エチル、アセ
トニトリル、ジメチルスルホキシド、ジメチルホルムア
ミド、ヘキサメチルリン酸トリアミド等又は之等の混合
溶媒を挙げることができる。また塩基性化合物としては
、例えば炭酸ナトリウム、炭酸カリウム、炭酸水素ナト
リウム、炭酸水素カリウム等の炭酸塩、水酸化ナトリウ
ム、水酸化カリウム等の金属水酸化物、水素化ナトリウ
ム、カリウム、ナトリウム、ナトリウムアミド、ナトリ
ウムメチラート、ナトリウムエチラート等の金属アルコ
ラ−1・、メチルリチウム、n−ブチルリチウム、フェ
ニルリチウム、リチウムジイソプロピルアミド等のアル
キル及びアリールリチウム又はリチウムアミド、ピリジ
ン、ジメチルアミノピリジン、トリエチルアミン、1,
5−ジアザビシクロ[4,3,O] ノネン−5(DB
N)、1.8−ジアザビシクロ[5,4,0]ウンデセ
ン7 (DBU) 、1.4−ジアザビシクロ[2゜2
.2]オクタン(DABCO)等の有機塩基等又はこれ
らの2s以上の混合物等を挙げることができる。−設入
(1a)の化合物と一般式(8)の化合物との使用割合
は、特に限定がなく広い範囲で適宜選択すればよいが、
前者に対して後者を少なくとも等モル量程度、好ましく
は等モル−5倍モル量程度使用するのがよい。該反応は
通常50〜120°C程度、好ましくは一40〜100
°C程度の温度下に行なわれ、一般に30分〜50時間
程度で終了する。- The reaction between the compound of installation (1a) and the compound of general formula (8) is generally carried out in a suitable inert solvent in the presence or absence of a basic compound. Examples of inert solvents used include aromatic hydrocarbons such as benzene, toluene, and xylene, ethers such as tetrahydrofuran, dioxane, and diethylene glycol dimethyl ether, lower alcohols such as methanol, ethanol, isopropanol, and butanol, heptane, Examples include aliphatic hydrocarbons such as hexane and cyclohexane, acetic acid, ethyl acetate, acetonitrile, dimethyl sulfoxide, dimethyl formamide, hexamethyl phosphoric acid triamide, and mixed solvents thereof. Examples of basic compounds include carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate, metal hydroxides such as sodium hydroxide and potassium hydroxide, sodium hydride, potassium, sodium, and sodium amide. , metal alcohols such as sodium methylate and sodium ethylate, alkyl and aryl lithium or lithium amides such as methyllithium, n-butyllithium, phenyllithium, lithium diisopropylamide, pyridine, dimethylaminopyridine, triethylamine, 1,
5-Diazabicyclo[4,3,O] nonene-5 (DB
N), 1,8-diazabicyclo[5,4,0]undecene7 (DBU), 1,4-diazabicyclo[2゜2
.. 2] Organic bases such as octane (DABCO), etc., or mixtures thereof of 2s or more can be mentioned. - The usage ratio of the compound of installation (1a) and the compound of general formula (8) is not particularly limited and may be appropriately selected within a wide range,
It is preferable to use the latter in at least an equimolar amount to the former, preferably in an equimolar to about 5 times the molar amount. The reaction is usually carried out at about 50 to 120°C, preferably about -40 to 100°C.
The process is carried out at a temperature of about °C and generally takes about 30 minutes to 50 hours to complete.
化合物(1a)を化合物(1f)に導く反応は、適当な
溶媒中又は無溶媒下、酸化剤の存在下に行なわれる。使
用される酸化剤としては、例えば無水酢酸−ジメチルス
ルホキシド、五酸化リン−ジメチルスルホキシド、ジシ
クロヘキシルカルボジイミド−ジメチルスルホキシド、
オキサリルクロリド、クロム酸、クロム酸−ピリジニウ
ム塩、クロム酸−2−ピリジニウム塩等のクロム酸塩、
二酸化マンガン等を挙げることができる。また、酸化剤
としてオキサリルクロリドを用いる場合には、前記反応
式−2の化合物(2)と化合物(4)で用いたのと同じ
塩基性化合物を添加するのがよい。The reaction for converting compound (1a) into compound (1f) is carried out in a suitable solvent or in the absence of a solvent in the presence of an oxidizing agent. Examples of the oxidizing agent used include acetic anhydride-dimethyl sulfoxide, phosphorus pentoxide-dimethyl sulfoxide, dicyclohexylcarbodiimide-dimethyl sulfoxide,
Chromates such as oxalyl chloride, chromic acid, chromic acid-pyridinium salt, chromic acid-2-pyridinium salt,
Examples include manganese dioxide. Further, when oxalyl chloride is used as the oxidizing agent, it is preferable to add the same basic compound as used in compound (2) and compound (4) of Reaction Formula-2 above.
ここで使用される溶媒としては、前述の芳香族炭化水素
類、低級アルコール類、ハロゲン化炭化水素類、エーテ
ル類、ジメチルスルホキシド、ジメチルホルムアミド、
ヘサメチルリン酸トリアミド等の極性溶媒等が挙げられ
る。反応は、通常0〜150°C1好ましくは室温〜1
00°C付近の温度下に行なわれ、1〜30時間程度に
て終了する。The solvents used here include the aforementioned aromatic hydrocarbons, lower alcohols, halogenated hydrocarbons, ethers, dimethyl sulfoxide, dimethylformamide,
Examples include polar solvents such as hesamethyl phosphoric triamide. The reaction is usually carried out at 0 to 150°C, preferably at room temperature to 1
It is carried out at a temperature around 00°C and is completed in about 1 to 30 hours.
酸化剤の使用量は、化合物(1a)に対して通常等モル
−20倍モル、好ましくは等モル−10倍モル量とする
のがよい。The amount of the oxidizing agent to be used is usually equivalent to 20 times the amount of compound (1a), preferably equivalent to 10 times the amount.
[反応式−4]
H(1g)
[式中R,R3、R’ 、ASB、l! 、m及びカル
ボスチリル骨格の3,4位の結合は前記に同じ。[Reaction formula-4] H (1 g) [In the formula, R, R3, R', ASB, l! , m and the bonds at the 3rd and 4th positions of the carbostyril skeleton are the same as above.
但し、基−(B)m−CH2−の炭素数は6をこえない
ものとする。]
上記還元反応には、水素化還元剤を用いる還元法が好適
に利用される。用いられる水素化還元剤としては、例え
ば水素化アルミニウムリチウム、水素化硼素ナトリウム
、ジボラン等が挙げられ、その使用量は原料化合物に対
して少なくとも等モル、好ましくは等モル−15倍モル
の範囲である。However, the number of carbon atoms in the group -(B)m-CH2- shall not exceed 6. ] In the above-mentioned reduction reaction, a reduction method using a hydrogenation reducing agent is suitably used. Examples of the hydrogenation reducing agent used include lithium aluminum hydride, sodium borohydride, diborane, etc., and the amount used is at least equimolar to the raw material compound, preferably in the range of equimolar to 15 times the molar amount. be.
この還元反応は、通常適当な溶媒、例えば水、メタノー
ル、エタノール、イソプロパツール等の低級アルコール
類、テトラヒドロフラン、ジエチルエーテル、ジイソプ
ロピルエーテル、ジグライム等のエーテル類やこれらの
混合溶媒等を用い、通常的−60〜150℃、好ましく
は一30〜100℃にて、約10分間〜5時間程度で行
われる。This reduction reaction is usually carried out using an appropriate solvent, such as water, lower alcohols such as methanol, ethanol, and isopropanol, ethers such as tetrahydrofuran, diethyl ether, diisopropyl ether, and diglyme, and mixed solvents thereof. It is carried out at -60 to 150°C, preferably -30 to 100°C, for about 10 minutes to 5 hours.
尚、還元剤として水素化アルミニウムリチウムやジボラ
ンを用いた場合には、テトラヒドロフラン、ジエチルエ
ーテル、ジイソプロピルエーテル、ジグライム等の無水
の溶媒を用いるのがよい。In addition, when lithium aluminum hydride or diborane is used as a reducing agent, it is preferable to use an anhydrous solvent such as tetrahydrofuran, diethyl ether, diisopropyl ether, diglyme, or the like.
[反応式−5]
0H
(1i)
(1j)
[式中、R,R’ 、B、m及びカルボスチリル骨格の
3,4位の結合は前記に同じ。]
化合物(11)を化合物(1j)に導く反応は、溶媒の
存在下又は非存在下、酸又は塩基性化合物の存在下に行
うことができる。[Reaction formula-5] 0H (1i) (1j) [In the formula, R, R', B, m and the bonds at the 3rd and 4th positions of the carbostyril skeleton are the same as above. ] The reaction for leading compound (11) to compound (1j) can be carried out in the presence or absence of a solvent, and in the presence of an acid or a basic compound.
ここで使用される溶媒としては、例えばピリジン、ジア
セトンアルコール、ユリジン、ジメチルホルムアミド、
ジメチルスルホキシド等の極性溶媒、テトラヒドロフラ
ン等のエーテル類、ベンゼンスルホン酸、ベンゼン、キ
シレン等の芳香族炭化水素類、無水酢酸等の低級アルカ
ン酸無水物、酢酸等の低級アルカン酸、メタノール、エ
タノール等の低級アルコール類等を例示できる。Examples of the solvent used here include pyridine, diacetone alcohol, uridine, dimethylformamide,
Polar solvents such as dimethyl sulfoxide, ethers such as tetrahydrofuran, aromatic hydrocarbons such as benzenesulfonic acid, benzene, xylene, lower alkanoic anhydrides such as acetic anhydride, lower alkanoic acids such as acetic acid, methanol, ethanol, etc. Examples include lower alcohols.
酸としては、塩酸、硫酸、臭化水素酸、ホウ酸、N−ブ
ロモアセタミド−二酸化硫黄、フロリシル商標名、粉末
状マグネシア−シリカ)−ヨウド、メシチルクロリド−
二酸化硫黄、メチルクロロスルフィド、ナフタレン−β
−スルホン酸、蓚酸、ホスホリルクロリド、無水フター
ル酸、チオニルクロリド、p−トルエンスルホン酸、p
−1ルエンスルホニルクロリド、五酸化リン、硫酸水素
カリウム等を例示できる。Examples of acids include hydrochloric acid, sulfuric acid, hydrobromic acid, boric acid, N-bromoacetamide-sulfur dioxide, Florisil brand name, powdered magnesia (silica)-iodine, mesityl chloride-
Sulfur dioxide, methylchlorosulfide, naphthalene-β
-Sulfonic acid, oxalic acid, phosphoryl chloride, phthalic anhydride, thionyl chloride, p-toluenesulfonic acid, p
Examples include -1 luenesulfonyl chloride, phosphorus pentoxide, and potassium hydrogen sulfate.
塩基性化合物としては、水酸化ナトリウム、水酸化カリ
ウム等のアルカリ金属水酸化物、トリエチルアミン等の
有機塩基等を例示できる。Examples of the basic compound include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and organic bases such as triethylamine.
酸又は塩基性化合物は、化合物(11)に対して通常等
モル−大過剰使用するのがよい。該反応は一般に室温〜
−200℃、好ましくは室温〜150℃付近にて1〜1
0時間程度にて終了する。The acid or basic compound is preferably used in a large equimolar excess relative to compound (11). The reaction is generally carried out at room temperature
1 to 1 at -200℃, preferably around room temperature to 150℃
It ends in about 0 hours.
[反応式−6] ることのあるアミノ低級アルキル基を示す。[Reaction formula-6] Indicates an amino lower alkyl group that may be
R7及びR8は同−又は異なって水素原子又は低級アル
キル基を示す。]
化合物(1k)と化合物(9)の反応は、前記反応式−
3の化合物(1a)と化合物(8)の反応と同様の条件
下に行われる。また該反応は、ヨウ化ナトリウム、ヨウ
化カリウム等のアルカリ金属ヨウ化物を添加することに
より、有利に進行する。R7 and R8 are the same or different and represent a hydrogen atom or a lower alkyl group. ] The reaction between compound (1k) and compound (9) is expressed by the above reaction formula -
The reaction is carried out under the same conditions as the reaction of compound (1a) and compound (8) in 3. Further, the reaction proceeds advantageously by adding an alkali metal iodide such as sodium iodide or potassium iodide.
上記の、出発原料化合物(2)は、例えば下記反応式に
従って製造できる。The above starting material compound (2) can be produced, for example, according to the following reaction formula.
[式中、R’ 、A、B、l Sm及びカルボスチリル
骨格の3,4位の結合は前記に同じ。Raはハロゲン原
子を1個有する低級アルキル基を示す。Rbは置換基と
して低級アルキル基を有す[反応式−7コ
(2a)
[式中、Rは前記に同じ。R9は低級アルコキシ基を示
す。]
化合物(10)と化合物(11)の反応は、通常のアミ
ド結合生成反応にて反応させる方法を利用できる。該ア
ミド結合生成反応としては公知のアミノ結合生成反応の
条件を容易に適用することができる。例えば(イ)混合
酸無水物法、即ちカルボン酸(11)にアルキルハロカ
ルボン酸を反応させて混合酸無水物とし、これにアミン
(10)を反応させる方法、(ロ)活性エステル法、即
ちカルボン酸(11)をp−ニトロフェニルエステル、
N−ヒドロキシコハク酸イミドエステル、1−ヒドロキ
シベンゾトリアゾールエステル等の活性エステルとし、
これにアミン(10)を反応させる方法、(ハ)カルボ
ジイミド法、即ちカルボン酸(11)にアミン(10)
をジシクロへキシルカルボジイミド、カルボニルジイミ
ダゾール等の活性化剤の存在下に縮合させる方法、(ニ
)その他の方法として、カルボン酸(11)を無水酢酸
等の脱水剤によりカルボン酸無水物とし、これにアミン
(10)を反応させる方法、カルボン酸(11)と低級
アルコールとのエステルにアミン(10)を高圧高温下
に反応させる方法、カルボン酸(11)の酸ハロゲン化
物即ちカルボン酸/”tライドにアミン(10)を反応
させる方法等を挙げることかできる。[In the formula, R', A, B, lSm and the bonds at the 3rd and 4th positions of the carbostyril skeleton are the same as above. Ra represents a lower alkyl group having one halogen atom. Rb has a lower alkyl group as a substituent [Reaction formula-7(2a)] [wherein R is the same as above]. R9 represents a lower alkoxy group. ] Compound (10) and compound (11) can be reacted by a conventional amide bond forming reaction. Conditions for known amino bond forming reactions can be easily applied to the amide bond forming reaction. For example, (a) mixed acid anhydride method, i.e., a method in which carboxylic acid (11) is reacted with an alkylhalocarboxylic acid to form a mixed acid anhydride, and this is reacted with amine (10), (b) active ester method, i.e. carboxylic acid (11) as p-nitrophenyl ester,
Active esters such as N-hydroxysuccinimide ester and 1-hydroxybenzotriazole ester,
A method in which amine (10) is reacted with this, (iii) carbodiimide method, that is, amine (10) is reacted with carboxylic acid (11).
(2) Another method is to convert carboxylic acid (11) into a carboxylic acid anhydride with a dehydrating agent such as acetic anhydride. A method of reacting an amine (10) with an ester of a carboxylic acid (11) and a lower alcohol under high pressure and high temperature. Examples include a method of reacting the amine (10) with a ride.
混合酸無水物法(イ)において用いられる混合酸無水物
は、通常のショツテン−バウマン反応により得られ、こ
れを通常単離することなくアミン(10)と反応させる
ことにより一般式(12)の化合物が製造される。ショ
ツテン−バウマン反応は塩基性化合物の存在下に行なわ
れる。用いられる塩基性化合物としては、ショツテン−
バウマン反応に慣用の化合物が用いられ、例えばトリエ
チルアミン、トリメチルアミン、ピリジン、ジメチルア
ニリン、N−メチルモルホリン、1,5ジアザビシクロ
[4,3,03ノネン−5(DBN)、1.8−ジアザ
ビシクロ[5,4,0)ウンデセン−7(DBU) 、
1.4−ジアザビシクロ[2,2,2〕オクタン(DA
BCO)等の有機塩基、炭酸カリウム、炭酸ナトリウム
、炭酸水素カリウム、炭酸水素ナトリウム等の無機塩基
等が挙げられる。該反応は、通常−20〜100°C1
好ましくは0〜50°C程度において行なわれ、反応時
間は5分〜10時間程度、好ましくは5分〜2時間程度
である。得られた混合酸無水物とアミン(10)との反
応は通常−20〜150°C程度、好ましくは10〜1
00℃程度において行なわれ、反応時間は5分〜10時
間程度、好ましくは5分〜5時間程度である。混合酸無
水物法は、一般に溶媒中で行なわれる。用いられる溶媒
は、混合酸無水物法に慣用の溶媒がいずれも使用可能で
あり、具体的には塩化メチレン、クロロホルム、ジクロ
ロエタン等のハロゲン化炭化水素類、ベンゼン、トルエ
ン、キシレン等の芳香族炭化水素類、ジエチルエーテル
、ジイソプロピルエーテル、テトラヒドロフラン、ジメ
トキシエタン等のエーテル類、酢酸メチル、酢酸エチル
等のエステル類、N、 N−ジメチルホルムアミド、ジ
メチルスルホキシド、ヘキサメチルリン酸トリアミド等
の非プロトン性極性溶媒等又は之等の混合溶媒等が挙げ
られる。The mixed acid anhydride used in the mixed acid anhydride method (a) is obtained by the usual Schotten-Baumann reaction, and is usually reacted with the amine (10) without isolation to form the compound of general formula (12). A compound is produced. The Schotten-Baumann reaction is carried out in the presence of a basic compound. As the basic compound used, Schotten-
Compounds customary for the Baumann reaction are used, for example triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4,3,03nonene-5 (DBN), 1,8-diazabicyclo[5, 4,0) Undecene-7 (DBU),
1.4-diazabicyclo[2,2,2]octane (DA
Examples include organic bases such as BCO), and inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate. The reaction is usually carried out at -20 to 100°C
Preferably, the reaction is carried out at about 0 to 50°C, and the reaction time is about 5 minutes to 10 hours, preferably about 5 minutes to 2 hours. The reaction between the obtained mixed acid anhydride and amine (10) is usually carried out at about -20 to 150°C, preferably at about 10 to 1
The reaction time is about 5 minutes to 10 hours, preferably about 5 minutes to 5 hours. Mixed anhydride methods are generally carried out in a solvent. Any solvent commonly used in the mixed acid anhydride method can be used as the solvent, specifically halogenated hydrocarbons such as methylene chloride, chloroform, and dichloroethane, and aromatic hydrocarbons such as benzene, toluene, and xylene. Hydrogens, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dimethoxyethane, esters such as methyl acetate, ethyl acetate, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, etc. or a mixed solvent such as these.
混合酸無水物法において使用されるアルキルハロカルボ
ン酸としては、例えばクロロ蟻酸メチル、ブロモ蟻酸メ
チル、クロロ蟻酸エチル、ブロモ蟻酸エチル、クロロ蟻
酸イソブチル等が挙げられる。Examples of the alkylhalocarboxylic acids used in the mixed acid anhydride method include methyl chloroformate, methyl bromoformate, ethyl chloroformate, ethyl bromoformate, isobutyl chloroformate, and the like.
該法におけるカルボン酸(11)とアルキルハロカルボ
ン酸とアミン(10)の使用割合は、通常等モルずつと
するのがよいが、アミン(10)に対してアルキルハロ
カルボン酸及びカルボン酸(11)はそれぞれ1〜1.
5倍モル量程度の範囲内で使用することができる。In this method, the proportions of carboxylic acid (11), alkylhalocarboxylic acid, and amine (10) to be used are usually equal moles. ) are respectively 1 to 1.
It can be used within a range of about 5 times the molar amount.
また前記その他の方法(ニ)の内で、カルボン酸ハライ
ドにアミン(10)を反応させる方法を採用する場合、
該反応は塩基性化合物の存在下に、適当な溶媒中で行な
われる。用いられる塩基性化合物としては、公知のもの
を広く使用でき、例えば上記ショツテン−バウマン反応
に用いられる塩基性化合物の他に、例えば水酸化ナトリ
ウム、水酸化カリウム、水素化ナトリウム、水素化カリ
ウム等を挙げることができる。また溶媒としては、例え
ば上記混合酸無水物法に用いられる溶媒の他に、メタノ
ール、エタノール、プロパツール、ブタノール、3−メ
トキシ−1−ブタノール、エチルセロソルブ、メチルセ
ロソルブ等のアルコール類、アセトニトリル、ピリジン
、アセトン等を挙げることができる。アミン(10)と
力・ルボン酸ハライドとの使用割合は、特に限定がなく
広い範囲内で適宜選択すればよいが、通常前者に対して
後者を少な(とも等モル量程度、好ましくは等モル−5
倍モル量程度用いるのがよい。該反応は、通常−20〜
180℃程度、好ましくは0〜150°C程度にて行な
われ、一般に5分〜30時間程度で完結する。Furthermore, among the other methods (d) above, when adopting a method of reacting the amine (10) with the carboxylic acid halide,
The reaction is carried out in a suitable solvent in the presence of a basic compound. As the basic compound used, a wide variety of known ones can be used. For example, in addition to the basic compounds used in the Schotten-Baumann reaction, for example, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, etc. can be mentioned. Examples of solvents include, for example, in addition to the solvents used in the mixed acid anhydride method, alcohols such as methanol, ethanol, propatool, butanol, 3-methoxy-1-butanol, ethyl cellosolve, and methyl cellosolve, acetonitrile, and pyridine. , acetone, etc. The ratio of the amine (10) to the carboxylic acid halide is not particularly limited and may be appropriately selected within a wide range, but usually the latter is smaller than the former (about equimolar amounts, preferably equimolar). -5
It is preferable to use about twice the molar amount. The reaction is usually -20~
It is carried out at about 180°C, preferably about 0 to 150°C, and is generally completed in about 5 minutes to 30 hours.
アミド結合生成反応は、カルボン酸(11)とアミン(
10)とを、トリフェニルホスフィン、ジフェニルホス
フィニルクロリド、フェニル−Nフェニルホスホラミド
クロリデート、ジエチル3つ
クロロホスフェート、ジエチルシアノホスホネート、ビ
ス(2−オキソ−3−オキサゾリジニル)ホスフィニッ
ククロリド等のリン化合物の縮合剤の存在下に反応させ
る方法によっても実施できる。The amide bond formation reaction involves carboxylic acid (11) and amine (
10) and triphenylphosphine, diphenylphosphinyl chloride, phenyl-N phenylphosphoramide chloridate, diethyl trichlorophosphate, diethylcyanophosphonate, bis(2-oxo-3-oxazolidinyl)phosphinic chloride, etc. It can also be carried out by a method of reacting a phosphorus compound in the presence of a condensing agent.
該反応は、上記カルボン酸ハライドにアミン(10)を
反応させる方法で用いられる溶媒及び塩基性化合物の存
在下に、通常−20〜150°C程度、好ましくは0〜
100°C程度付近にて行われ、一般に5分〜30時間
程度にて終了する。縮合剤及びカルボン酸(11)の使
用量はアミン(10)に対してそれぞれ少なくとも等モ
ル量程度、好ましくは等モル−2倍モル量程度とするの
がよい。The reaction is carried out in the presence of the solvent and basic compound used in the method of reacting the carboxylic acid halide with the amine (10), usually at about -20 to 150°C, preferably at 0 to 150°C.
The process is carried out at around 100°C and generally takes about 5 minutes to 30 hours to complete. The amounts of the condensing agent and the carboxylic acid (11) to be used are at least equimolar, preferably equimolar to twice the molar amount of the amine (10).
化合物(12)を環化して化合物(2a)に導く反応は
、酸の存在下無溶媒で又は適当な溶媒中で行われる。The reaction of cyclizing compound (12) to lead to compound (2a) is carried out in the presence of an acid without a solvent or in an appropriate solvent.
使用される酸としては、例えは塩酸、硫酸、臭化水素酸
、硝酸、ポIJ IJリン酸無機酸、p−トルエンスル
ホン酸、エタンスルホン酸、トリフルオロ酢酸等の有機
酸等を例示できる。Examples of the acids used include organic acids such as hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, inorganic acids such as polyphosphoric acid, p-toluenesulfonic acid, ethanesulfonic acid, and trifluoroacetic acid.
使用される溶媒としては反応に悪影響を与えないもので
あればいずれも使用でき、例えば水、メタノール、エタ
ノール、プロパツール、ブタノール、3−メトキシ−1
−ブタノール、エチルセロソルブ、メチルセロソルブ等
のアルコール類、ピリジン、アセトン等、塩化メチレン
、クロロホルム、ジクロロエタン等のハロゲン化炭化水
素類、ベンゼン、トルエン、キシレン等の芳香族炭化水
素類、ジエチルエーテル、テトラヒドロフラン、ジメト
キシエタン、ジフェニルエーテル等のエーテル類、酢酸
メチル、酢酸エチル等のエステル類、N、N−ジメチル
ホルムアミド、ジメチルスルホキシド、ヘキサメチルリ
ン酸トリアミド等の非プロトン性極性溶媒又はそれらの
混合溶媒等が挙げられる。該反応は通常−20〜150
°C程度、好ましくは0〜150°C程度にて行われ、
一般に5分〜30時間程度で終了する。Any solvent can be used as long as it does not adversely affect the reaction, such as water, methanol, ethanol, propatool, butanol, and 3-methoxy-1.
-Alcohols such as butanol, ethyl cellosolve, methyl cellosolve, pyridine, acetone, etc., halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane, etc., aromatic hydrocarbons such as benzene, toluene, xylene, diethyl ether, tetrahydrofuran, Examples include ethers such as dimethoxyethane and diphenyl ether, esters such as methyl acetate and ethyl acetate, aprotic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, and hexamethyl phosphate triamide, or mixed solvents thereof. . The reaction is usually -20 to 150
It is carried out at about °C, preferably about 0 to 150 °C,
Generally, it takes about 5 minutes to 30 hours to complete.
[反応式−8]
)(H
(13) (14) (2b)
[式中Rは前記に同じ。]
上記反応式中、化合物(13)を閉環させて化合物(1
4)に導く反応は、N、 N−置換ホルムアミドと酸触
媒(一般にヴイルスマイヤー試薬と呼ばれる)の存在下
に適当な溶媒中又は溶媒の非存在下に行われる。ここで
使用されるN、 N−置換ホルムアミドとしては、N、
N−ジメチルホルムアミド、N、N−ジエチルホルムア
ミド、Nエチル−N−メチルホルムアミド、N−メチル
N−フェニルホルムアミド等を例示できる。酸触媒とし
ては、オキシ塩化リン、チオニルクロライド、フォスゲ
ン等を例示できる。使用される溶媒としては、クロロホ
ルム、1,2−ジクロロエタン、1,2−ジクロロエチ
レン等のハロゲン化炭化水素類、クロロベンゼン、1,
2−ジクロロベンゼン等の芳香族炭化水素類等を例示で
きる。N。[Reaction formula-8] )(H (13) (14) (2b)
[In the formula, R is the same as above. ] In the above reaction formula, compound (13) is ring-closed to form compound (1
The reaction leading to 4) is carried out in the presence of an N,N-substituted formamide and an acid catalyst (commonly referred to as Willsmeier reagent) in a suitable solvent or in the absence of a solvent. The N,N-substituted formamide used here includes N,
Examples include N-dimethylformamide, N,N-diethylformamide, N-ethyl-N-methylformamide, and N-methylN-phenylformamide. Examples of acid catalysts include phosphorus oxychloride, thionyl chloride, and phosgene. Solvents used include chloroform, halogenated hydrocarbons such as 1,2-dichloroethane, and 1,2-dichloroethylene, chlorobenzene, 1,
Examples include aromatic hydrocarbons such as 2-dichlorobenzene. N.
N−置換ホルムアミドと酸触媒の使用量は、化合物(1
3)に対して、通常大過剰量、好ましくは、前者は2〜
5倍モル、後者は5〜10倍モル量とするのがよい。反
応温度は通常0〜150°C1好ましくは50〜100
°C付近で行うのがよい。反応は3〜24時間程時間路
了する。The amounts of N-substituted formamide and acid catalyst used are as follows:
3), the former is usually in large excess, preferably 2 to
The amount is preferably 5 times the molar amount, and the latter is preferably 5 to 10 times the molar amount. The reaction temperature is usually 0 to 150°C, preferably 50 to 100°C.
It is best to do this at around °C. The reaction takes about 3 to 24 hours to complete.
また化合物(14)から化合物(2b)を得る反応は、
化合物(14)を例えば塩酸、臭化水素酸等のハロゲン
化水素酸類、硫酸、リン酸等の無機酸類、水酸化カリウ
ム、水酸化ナトリウム等のアルカリ金属水酸化物、炭酸
ナトリウム、炭酸カリウム、炭酸水素カリウム等の無機
アルカリ化合物、或いは酢酸等の有機酸の存在下に、5
0〜150℃、好ましくは70〜120℃にて、0.5
〜24時間程時間熱することにより行なわれる。Moreover, the reaction to obtain compound (2b) from compound (14) is
Compound (14) can be used, for example, with hydrohalic acids such as hydrochloric acid and hydrobromic acid, inorganic acids such as sulfuric acid and phosphoric acid, alkali metal hydroxides such as potassium hydroxide and sodium hydroxide, sodium carbonate, potassium carbonate, and carbonic acid. In the presence of an inorganic alkali compound such as potassium hydrogen, or an organic acid such as acetic acid,
At 0 to 150°C, preferably 70 to 120°C, 0.5
This is done by heating for about 24 hours.
[反応式−9コ
[式中R及びカルボスチリル骨格の3,4位の結合は前
記に同じ。RIGは水素原子又は低級アルキル基を示す
。]
化合物(15)の還元反応は、通常、水素化還元剤を用
いて行われる。その水素化還元剤としては、例えば水素
化硼素ナトリウム、水素化アルミニウムリチウム、シボ
ラン等が挙げられ、その使用量は、通常、化合物(15
)に対して少なくとも等モル程度、好ましくは等モル−
3倍モルの範囲である。この還元反応は、通常、適当な
溶媒、例えば水、メタノール、エタノール、イソプロパ
ツール等の低級アルコール類、テトラヒドロフラン、エ
チルエーテル、ジグライム等のエーテル類等を用い、約
−60〜50°C1好ましくは一り0℃〜室温にて、約
10分間〜5時間熱度で行われる。尚、還元剤として水
素化アルミニウムリチウムやジボランを用いた場合には
、エチルエーテル、テトラヒドロフラン、ジグライム等
の無水の溶媒を用いるのがよい。[Reaction formula-9] [In the formula, R and the bonds at the 3 and 4 positions of the carbostyril skeleton are the same as above. RIG represents a hydrogen atom or a lower alkyl group. ] The reduction reaction of compound (15) is usually carried out using a hydrogenation reducing agent. Examples of the hydrogenation reducing agent include sodium borohydride, lithium aluminum hydride, siborane, etc., and the amount used is usually determined by the amount of the compound (15
), preferably at least equimolar to
The range is 3 times the mole. This reduction reaction is usually carried out using a suitable solvent such as water, lower alcohols such as methanol, ethanol and isopropanol, ethers such as tetrahydrofuran, ethyl ether and diglyme, and preferably at a temperature of about -60 to 50°C. The heating is carried out at 0° C. to room temperature for about 10 minutes to 5 hours. In addition, when lithium aluminum hydride or diborane is used as a reducing agent, it is preferable to use an anhydrous solvent such as ethyl ether, tetrahydrofuran, or diglyme.
また、上記の還元反応は、適当な還元触媒の存在下に接
触還元することによっても行われる。用いられる還元触
媒としては、例えば白金、酸化白金、パラジウム黒、パ
ラジウム炭素、ラネーニッケル等の通常の接触還元用触
媒が含まれ、その使用量は化合物(15)に対し、通常
的0.2〜0.5重量倍の範囲である。この接触還元は
、例えば水、メタノール、エタノール、イソプロパツー
ル、テトラヒドロフラン、エチルエーテル等の溶媒中に
て、1〜10気圧、好ましくは1〜3気圧の水素雰囲気
下、−30°C〜溶媒の沸点温度、好ましくは0°C〜
室温付近にて、よく振り混ぜることにより行われる。Further, the above reduction reaction is also carried out by catalytic reduction in the presence of a suitable reduction catalyst. Examples of the reduction catalyst used include ordinary catalysts for catalytic reduction such as platinum, platinum oxide, palladium black, palladium carbon, and Raney nickel, and the amount used is usually 0.2 to 0. The range is .5 times the weight. This catalytic reduction is carried out in a solvent such as water, methanol, ethanol, isopropanol, tetrahydrofuran, ethyl ether, etc. under a hydrogen atmosphere of 1 to 10 atm, preferably 1 to 3 atm, from -30°C to the temperature of the solvent. Boiling point temperature, preferably 0°C ~
This is done by shaking well at around room temperature.
[反応式−10]
(1m)
(1n)
[式中R,R1、A、B1、l及びmは前記に同じ]
上記の化合物(1m)を脱水素して化合物(1n)に導
く反応は、適当な溶媒中で脱水素剤の存在以下に行われ
る。脱水素剤としては、例えば2゜3−ジクロロ−5,
6−ジシアツベンゾキノン、2.3,5.6−テトラク
ロロペンゾキノン(−船名クロラニル)等のベンゾキノ
ン類、N−ブロモコハク酸イミド、N−クロロコハク酸
イミド、臭素等のハロゲン化剤、二酸化セレン、パラジ
ウム炭素、パラジウム黒、酸化パラジウム、ラネーニッ
ケル等の脱水素化触媒が挙げられる。その脱水素剤の使
用量は特に制限されないが、ハロゲン化剤の場合には、
通常、化合物(1m)に対し1〜5倍モル、好ましくは
1〜2倍モルとするのがよく、脱水素化触媒の場合には
、一般に過剰量とするのがよい。他の脱水素剤も通常等
モル〜過剰量用いる。溶媒としては、ジオキサン、テト
ラヒドロフラン、メトキシエタノール、ジメトキシエタ
ン等のエーテル類、ベンゼン、トルエン、キシレン、ク
メン等の芳香族炭化水素類、ジクロロメタン、ジクロロ
メタン、クロロホルム、四塩化炭素等のハロゲン化炭化
水素類、ブタノール、アミルアルコール、ヘキサノール
等のアルコール類、酢酸等の極性プロトン溶媒、ジメチ
ルホルムアミド、ジメチルスルホキシド、ヘキサメチル
リン酸トリアミド等の非プロトン性極性溶媒等が挙げら
れる。該反応は通常室温〜300°C1好ましくは室温
〜200°Cで行われ、一般に1〜40時間程時間路了
する。[Reaction formula-10] (1m) (1n) [In the formula, R, R1, A, B1, l and m are the same as above] The reaction of dehydrogenating the above compound (1m) to lead to compound (1n) is , carried out in a suitable solvent and in the presence of a dehydrogenating agent. As a dehydrogenating agent, for example, 2゜3-dichloro-5,
Benzoquinones such as 6-dicyazbenzoquinone, 2,3,5,6-tetrachloropenzoquinone (-ship name Chloranil), halogenating agents such as N-bromosuccinimide, N-chlorosuccinimide, bromine, and carbon dioxide. Examples include dehydrogenation catalysts such as selenium, palladium on carbon, palladium black, palladium oxide, and Raney nickel. The amount of the dehydrogenating agent used is not particularly limited, but in the case of a halogenating agent,
Usually, the amount is preferably 1 to 5 times, preferably 1 to 2 times the mole of the compound (1m), and in the case of a dehydrogenation catalyst, it is generally good to use an excess amount. Other dehydrogenating agents are also usually used in equimolar to excess amounts. Examples of solvents include ethers such as dioxane, tetrahydrofuran, methoxyethanol, and dimethoxyethane; aromatic hydrocarbons such as benzene, toluene, xylene, and cumene; halogenated hydrocarbons such as dichloromethane, dichloromethane, chloroform, and carbon tetrachloride; Examples include alcohols such as butanol, amyl alcohol, and hexanol, polar protic solvents such as acetic acid, and aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, and hexamethylphosphoric triamide. The reaction is usually carried out at room temperature to 300°C, preferably room temperature to 200°C, and is generally completed for about 1 to 40 hours.
また化合物(1n)を還元すれば化合物(1m)に導く
ことができる。この還元反応は通常の接触還元における
条件が適用され、例えば適当な溶媒中で金属触媒の存在
下に行われる。触媒としては、パラジウム、パラジウム
炭素、プラチナ、ラネーニッケル等の金属触媒が挙げら
れ、通常の触媒量にて用いられる。用いられる溶媒とし
ては、例えば水、メタノール、エタノール、イソプロパ
ツール、ジオキサン、テトラヒドロフラン、ヘキサン、
シクロヘキサン、酢酸エチル、又はこれらの混合溶媒等
が挙げられる。該反応は常圧及び加圧下のいずれでも行
い得るが、通常、常圧〜20kg/cm2にて、好まし
くは常圧〜10kg/Cm2にて、0〜150°C1好
ましくは室温〜100°Cで行われる。Further, by reducing compound (1n), compound (1m) can be obtained. This reduction reaction is carried out under the usual conditions for catalytic reduction, for example, in the presence of a metal catalyst in a suitable solvent. Examples of the catalyst include metal catalysts such as palladium, palladium on carbon, platinum, and Raney nickel, which are used in normal catalytic amounts. Examples of solvents used include water, methanol, ethanol, isopropanol, dioxane, tetrahydrofuran, hexane,
Examples include cyclohexane, ethyl acetate, and mixed solvents thereof. The reaction can be carried out either at normal pressure or under increased pressure, but usually at normal pressure to 20 kg/cm2, preferably at normal pressure to 10 kg/cm2, at 0 to 150°C, preferably at room temperature to 100°C. It will be done.
尚、本発明化合物(1)のうち、カルボスチリル骨格の
3位と4位間の結合が二重結合である化合物は、下記の
式で示されるように、ラクタムーラクチム型の互変異性
をとり得る。Among the compounds (1) of the present invention, compounds in which the bond between the 3rd and 4th positions of the carbostyryl skeleton is a double bond have tautomerism of the lactam lactim type, as shown by the formula below. can be taken.
[式中、R,、R’ 、A、B5−5及びmは前記に同
じ。]
一般式(1)の化合物の中、R1が低級アルキル基を有
することのあるピリジル基である化合物は、これを前記
反応式−3の化合物(1C)を化合物(1d)に導く反
応と同様の条件下に接触還元することにより、R1が低
級アルキル基を有することのあるピペリジニル基である
化合物に導くことができる。該反応は、塩酸等の酸を添
加することにより有利に進行する。[In the formula, R,, R', A, B5-5 and m are the same as above. ] Among the compounds of general formula (1), compounds in which R1 is a pyridyl group that may have a lower alkyl group are treated in the same manner as in the reaction for converting compound (1C) to compound (1d) in Reaction Formula-3 above. By catalytic reduction under these conditions, a compound in which R1 is a piperidinyl group which may have a lower alkyl group can be obtained. The reaction proceeds advantageously by adding an acid such as hydrochloric acid.
本発明の一般式(1)で表わされるカルボスチリル誘導
体は、医薬的に許容される酸を作用さぜることにより容
易に酸付加塩を形成させることができる。核酸としては
、例えば塩酸、硫酸、リン酸、臭化水素酸等の無機酸、
シュウ酸、マレイン酸、フマール酸、リンゴ酸、酒石酸
、クエン酸、安息香酸等の有機酸を挙げることができる
。The carbostyril derivative represented by the general formula (1) of the present invention can be easily formed into an acid addition salt by reacting with a pharmaceutically acceptable acid. Examples of nucleic acids include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid;
Organic acids such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, and benzoic acid can be mentioned.
本発明の一般式(1)で表わされるカルボスチリル誘導
体は、医薬的に許容される塩基性化合物を作用させるこ
とにより容易に塩を形成させることができる。該塩基性
化合物としては、例えば水酸化ナトリウム、水酸化カリ
ウム、水酸化カルシウム、炭酸ナトリウム、炭酸水素カ
リウム等を挙げることができる。また、ヨウ化メチル、
塩化エチル等のハロゲン化アルキル等を作用させたりす
ることにより四級塩を形成させることができる。The carbostyryl derivative represented by the general formula (1) of the present invention can easily form a salt by reacting with a pharmaceutically acceptable basic compound. Examples of the basic compound include sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium hydrogen carbonate, and the like. Also, methyl iodide,
A quaternary salt can be formed by reacting with an alkyl halide such as ethyl chloride.
斯くして得られる各々の行程での目的化合物は、通常の
分離手段により容易に単離精製することができる。該分
離手段としては例えは溶媒抽圧法、希釈法、再結晶法、
カラムクロマI・グラフイープレパラテイブ薄層クロマ
トグラフィー等を例示できる。The target compounds obtained in each step can be easily isolated and purified by conventional separation means. Examples of the separation method include solvent extraction method, dilution method, recrystallization method,
Examples include Column Chroma I and GraphE Preparative Thin Layer Chromatography.
尚本発明は、光学異性体も当然に包含するものである。Note that the present invention naturally also includes optical isomers.
一般式(1)の化合物は、通常、一般的な医薬製剤の形
態で用いられる。製剤は通常使用される充填剤、増量剤
、結合剤、付湿剤、崩壊剤、表面活性剤、滑沢剤等の希
釈剤あるいは賦形剤を用いて調製される。この医薬製剤
としては各種の形態が治療目的に応じて選択でき、その
代表的なものとして錠剤、火剤、散剤、液剤、懸濁剤、
乳剤、顆粒剤、カプセル剤、串刺、注射剤(液剤、懸濁
剤等)等が挙げられる。錠剤の形態に成形するに際して
は、担体としてこの分野で従来公知のものを広く使用で
き、例えば乳糖、白糖、塩化ナトリウム、ブドウ糖、尿
素、デンプン、炭酸カルシウム、カオリン、結晶セルロ
ース、ケイ酸等の賦形剤、水、エタノール、プロパツー
ル、単シロップ、ブドウ糖液、デンプン液、ゼラチン溶
液、カルボキシメチルセルロース、セラック、メチルセ
ルロス、リン酸カリウム、ポリビニルピロリドン等の結
合剤、乾燥デンプン、アルギン酸ナトリウム、カンテン
末、ラミナラン末、炭酸水素ナトリウム、炭酸カルシウ
ム、ポリオキシエチレンソルビタン脂肪酸エステル類、
ラウリル硫酸すl・リウム、ステアリン酸モノグリセリ
ド、デンプン、乳糖等の崩壊剤、白糖、ステアリン、カ
カオバター、水素添加油等の崩壊抑制剤、第4級アンモ
ニウム塩基、ラウリル硫酸ナトリウム等の吸収促進剤、
グリセリン、デンプン等の保湿剤、デンプン、乳糖、カ
オリン、ベントナイト、コロイド状ケイ酸等の吸着剤、
精製タルク、ステアリン酸塩、ホウ酸末、ポリエチレン
グリコール等の滑沢剤等が例示できる。さらに錠剤は必
要に応じ通常の剤皮を施した錠剤、例えば糖衣錠、ゼラ
チン被包錠、腸溶被錠、フィルムコーティング錠あるい
は二重錠、多層錠とすることができる。火剤の形態に成
形するに際しては、担体としてこの分野で従来公知のも
のを広く使用でき、例えばブドウ糖、乳糖、デンプン、
カカオ脂、硬化植物油、カオリン、タルク等の賦形剤、
アラビアゴム末、トラガント末、ゼラチン、エタノール
等の結合剤、ラミナランカンテン等の崩壊剤等が使用で
きる。串刺の形態に成形するに際しては、担体として従
来公知のものを広く使用でき、例えばポリエチレングリ
コール、カカオ脂、高級アルコール、高級アルコールの
エステル類、ゼラチン、半合成グリセライド等を挙げる
ことができる。注射剤として調製される場合には、液剤
及び懸濁剤は殺菌され、かっ血液と等張であるのが好ま
しく、これら液剤、乳剤及び懸濁剤の形態に成形するに
際しては、希釈剤としてこの分野において慣用されてい
るものをすべて使用でき、例えば水、エチルアルコール
、プロピレングリコル、エトキシ化イソステアリルアル
コール、ポリオキシ化インステアリルアルコール、ポリ
オキシエチレンソルビタン脂肪酸エステル類等を挙げる
ことができる。なお、この場合等張性の溶液を調製する
に充分な量の食塩、ブドウ糖あるいはグリセリンを医薬
製剤中に含有させてもよく、また通常の溶解捕助剤、緩
衝剤、無痛化剤等を添加してもよい。更に必要に応じて
着色剤、保存剤、香料、風味剤、甘味剤等や他の医薬品
を医薬製剤11月こ含有させてもよい。The compound of general formula (1) is usually used in the form of a common pharmaceutical preparation. The formulation is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and lubricants. Various forms of this pharmaceutical preparation can be selected depending on the therapeutic purpose, and representative examples include tablets, gunpowder, powder, liquid, suspension, and
Examples include emulsions, granules, capsules, skewers, injections (solutions, suspensions, etc.). When forming tablets, a wide variety of carriers conventionally known in this field can be used, such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, etc. Excipients, water, ethanol, propatool, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, binders such as polyvinylpyrrolidone, dry starch, sodium alginate, agar powder, laminaran Sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters,
Disintegrants such as sulfur/lium lauryl sulfate, stearic acid monoglyceride, starch, and lactose; disintegration inhibitors such as white sugar, stearin, cocoa butter, and hydrogenated oil; absorption enhancers such as quaternary ammonium bases, and sodium lauryl sulfate;
Humectants such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic acid;
Examples include purified talc, stearate, boric acid powder, and lubricants such as polyethylene glycol. Furthermore, the tablets may be coated with a conventional coating, if necessary, such as dragee-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double-layered tablets, or multilayered tablets. When molding into the form of gunpowder, a wide variety of carriers conventionally known in this field can be used, such as glucose, lactose, starch,
Excipients such as cocoa butter, hydrogenated vegetable oil, kaolin, and talc,
Binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants such as laminalan agar can be used. When forming into a skewer, a wide variety of conventionally known carriers can be used, such as polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, and the like. When prepared as injections, solutions and suspensions are preferably sterilized and isotonic with blood stasis, and when formed into the form of solutions, emulsions and suspensions, this agent is used as a diluent. All those commonly used in the field can be used, such as water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated instearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and the like. In this case, a sufficient amount of salt, glucose, or glycerin to prepare an isotonic solution may be included in the pharmaceutical preparation, and usual solubilizing agents, buffers, soothing agents, etc. may be added. You may. Furthermore, if necessary, the pharmaceutical preparation may contain coloring agents, preservatives, perfumes, flavoring agents, sweeteners, and other pharmaceuticals.
本発明の医薬製剤中に含有されるべき一般式(1)の化
合物の量は、特に限定されず広い範囲から適宜選択でき
るが、通常全組成物中1〜70重量%、好ましくは1〜
30重合%である。The amount of the compound of general formula (1) to be contained in the pharmaceutical preparation of the present invention is not particularly limited and can be appropriately selected from a wide range, but is usually 1 to 70% by weight, preferably 1 to 70% by weight based on the total composition.
The polymerization rate is 30%.
本発明の医薬製剤の投与方法は特に制限はなく、各種製
剤形態、患者の年齢、性別その他の条件、疾患の程度等
に応じた方法で投与される。例えば錠剤、火剤、液剤、
懸濁剤、乳剤、顆粒剤及びカプセル剤の場合には経口投
与される。また注射剤の場合には単独であるいはブドウ
糖、アミノ酸等の通常の補液と混合して静脈内投与され
、更に必要に応じて単独で筋肉内、皮内、皮下もしくは
腹腔内投与される。半開の場合には直腸内投与される。There are no particular restrictions on the method of administering the pharmaceutical preparation of the present invention, and the method is determined depending on the various preparation forms, age, sex and other conditions of the patient, the severity of the disease, and the like. For example, tablets, gunpowder, liquid,
Suspensions, emulsions, granules and capsules are administered orally. In the case of an injection, it is administered intravenously alone or mixed with a normal replacement fluid containing glucose, amino acids, etc., and if necessary, it is administered alone intramuscularly, intradermally, subcutaneously, or intraperitoneally. If it is partially opened, it is administered rectally.
本発明の医薬製剤の投与量は用法、患者の年齢、性別そ
の他の条件、疾患の程度等により適宜選択されるが、通
常有効成分である一般式(1)の化合物の量が1日当り
体重1kg当り約0.1〜10mg程度となるように投
与するのがよい。また、投与単位形態中に有効成分を2
〜200mg含有させるのがよい。The dosage of the pharmaceutical preparation of the present invention is appropriately selected depending on the usage, age, sex and other conditions of the patient, degree of disease, etc., but usually the amount of the compound of general formula (1), which is the active ingredient, is 1 kg of body weight per day. It is preferable to administer about 0.1 to 10 mg per dose. It is also possible to contain two or more active ingredients in a dosage unit form.
It is preferable to contain up to 200 mg.
実施例
以下に参考例、実施例、薬理試験例及び製剤例を掲げる
。Examples Reference examples, working examples, pharmacological test examples, and formulation examples are listed below.
参考例1
60%水素化ナトリウム2.0gのジメチルホルムアミ
ド50m2懸濁液に、ヨウ化トリメチルスルホキソニウ
ムl1gを少しずつ加え、室温にて30分間攪拌した。Reference Example 1 To a suspension of 2.0 g of 60% sodium hydride in 50 m2 of dimethylformamide, 1 g of trimethylsulfoxonium iodide was added little by little, and the mixture was stirred at room temperature for 30 minutes.
8−メチル−3−ホルミルカルボスチリル4.7gを少
しずつ加え、10°Cにて1時間攪拌後、反応液を氷水
200m1月こ注ぎ込んだ。これに酢酸エチルを加えた
後、不溶物を炉別し、有機層を水洗、硫酸マグネシウム
にて乾燥し、溶媒を減圧濃縮して、1.0gの8−メチ
ル3−オキシラニルカルボスチリルを得た。4.7 g of 8-methyl-3-formylcarbostyryl was added little by little, and after stirring at 10°C for 1 hour, the reaction solution was poured into 200 ml of ice water. After adding ethyl acetate to this, insoluble matter was filtered out, the organic layer was washed with water, dried over magnesium sulfate, and the solvent was concentrated under reduced pressure to obtain 1.0 g of 8-methyl 3-oxiranylcarbostyryl. Obtained.
NMR(CDCf3)δ; 2−49 (3H,s) 2、 71 (IH,dd、 J=2. 5Hz。NMR(CDCf3)δ; 2-49 (3H, s) 2, 71 (IH, dd, J=2.5Hz.
6.0Hz) 3.22 (IH,dd、J=4.0Hz。6.0Hz) 3.22 (IH, dd, J=4.0Hz.
6.0Hz) 4.20 (IH,dd、J=2.5Hz。6.0Hz) 4.20 (IH, dd, J=2.5Hz.
4.0Hz)
7.14 (IH,t、J=7.5Hz)’l 34
(IH,d、J=7,5H,z)7.42 (IH,d
、J=7.5Hz)7.67 (IH,s)
9.36 (IH,brs)
参考例2
2−(4−クロロブチリル)アニリン3.22g及びピ
リジン1. 71+rM2をジエチルエーテル80贈に
溶かし、水冷攪拌下に60% 3−工トキシアクリリル
クロリド4.38gのジエチルエーテル20艦溶液を滴
下した。更に室温で一昼夜攪拌した。反応液に氷水を加
え、結晶を枦取し、水洗し、冷エタノール洗浄し、乾燥
し、4.82gのN−(3−エトキシアクリリル)−2
−(4クロロブチリル)アニリンを得た。4.0Hz) 7.14 (IH, t, J=7.5Hz)'l 34
(IH, d, J=7,5H, z) 7.42 (IH, d
, J=7.5Hz) 7.67 (IH, s) 9.36 (IH, brs) Reference Example 2 3.22 g of 2-(4-chlorobutyryl)aniline and 1. 71+rM2 was dissolved in 80 parts of diethyl ether, and a solution of 4.38 g of 60% 3-methoxyacrylyl chloride in 20 parts of diethyl ether was added dropwise while stirring while cooling with water. The mixture was further stirred at room temperature all day and night. Ice water was added to the reaction solution, the crystals were collected, washed with water, washed with cold ethanol, and dried to give 4.82 g of N-(3-ethoxyacrylyl)-2.
-(4chlorobutyryl)aniline was obtained.
NMR(CDCf3)δ;
1.37 (3H,t、J=7.0Hz)2.15〜2
.28 (2H,m)
3.25 (2H,t、J=7.0Hz)3.71 (
2H,t、J=7.0Hz)3.97 (2H,’ q
、J=7.0Hz)5.40 (IH,d、J=12.
0Hz)7.09 (IH,d−t、J=1.5Hz7
.0Hz)
7.55 (IH,d−’t、J=1.5Hz7、QH
z)
’l 67 (IH,d、J=12゜0Hz)7、
94 (IH,d−d、 J=1. 5Hz7、
0Hz)
8.83 (IH,d−d、 J=1. 5Hz7
、0Hz)
11、 57 (IH,brs)
参考例3
ポリリン酸48gにN−(3−エトキシアクリリル)−
2−(4−クロロブチリル)アニリンを加え、70°C
にて30分間加熱攪拌した。反応液を氷水中にあけ、析
出結晶を枦取し、水洗し、乾燥し、シリカゲルカラムク
ロマトグラフィー(溶出液;クロロホルム:酢酸エチル
−3=2)によす精製し、4−(3−クロロプロピル)
−3−ホルミルカルボスチリル2.29gを得た。NMR (CDCf3) δ; 1.37 (3H, t, J=7.0Hz) 2.15-2
.. 28 (2H, m) 3.25 (2H, t, J=7.0Hz) 3.71 (
2H, t, J=7.0Hz) 3.97 (2H,' q
, J=7.0Hz) 5.40 (IH, d, J=12.
0Hz) 7.09 (IH, d-t, J=1.5Hz7
.. 0Hz) 7.55 (IH, d-'t, J=1.5Hz7, QH
z)'l 67 (IH, d, J=12°0Hz)7,
94 (IH, dd, J=1.5Hz7,
0Hz) 8.83 (IH, dd, J=1.5Hz7
, 0Hz) 11, 57 (IH, brs) Reference Example 3 N-(3-ethoxyacrylyl)- to 48 g of polyphosphoric acid
Add 2-(4-chlorobutyryl)aniline and heat to 70°C.
The mixture was heated and stirred for 30 minutes. The reaction solution was poured into ice water, and the precipitated crystals were collected, washed with water, dried, and purified by silica gel column chromatography (eluent: chloroform:ethyl acetate-3=2). propyl)
2.29 g of -3-formylcarbostyril was obtained.
NMR(CDCJ3)δ;
2、 03〜2.22 (2H,m)
3.51 (2H,t、J=7.0Hz)3.78 (
2H,t、J=7.0Hz)7、 28〜7.48
(2H,m)7.65 (IH,t、 J=7.
5Hz)8、 02 (LH,d、 J=7. 5
Hz)10、 03 (LH,5)
12、 07 (IH,brs)
実施例1
2−ブロモピリジン10gのジエチルエーテル50雁溶
液に、−30〜−20°Cにて冷却攪拌下、15%n−
ブチルリチウムn−ヘキサン溶液41話を滴下した。同
温度にて30分間攪拌後、溶液を一30°Cにて冷却攪
拌下、8−メチル−3−ホルミルカルボスチリル4.0
gのテトラヒドロフラン50軛懸濁中に滴下した。同温
度にて30分間攪拌後、反応液に飽和塩化アンモニウム
水溶液を加え、減圧濃縮した。得られた残渣にジクロロ
メタンを加え、不溶物を?戸別後、水洗した。硫酸マグ
ネシウムにて乾燥し、溶媒を減圧濃縮して得られた残渣
をシリカゲルカラムクロマトグラフィー(溶出液;ジク
ロロロメタン:メタノールー20=1)にて精製した。NMR (CDCJ3) δ; 2, 03 ~ 2.22 (2H, m) 3.51 (2H, t, J = 7.0Hz) 3.78 (
2H, t, J=7.0Hz) 7, 28~7.48
(2H, m)7.65 (IH, t, J=7.
5Hz) 8, 02 (LH, d, J=7.5
Hz) 10, 03 (LH, 5) 12, 07 (IH, brs) Example 1 15% n was added to a solution of 10 g of 2-bromopyridine in 50 g of diethyl ether under cooling and stirring at -30 to -20°C. −
Butyllithium n-hexane solution 41 times was added dropwise. After stirring at the same temperature for 30 minutes, the solution was cooled at -30°C while stirring, 8-methyl-3-formylcarbostyryl 4.0
The mixture was added dropwise to a suspension of 50 g of tetrahydrofuran. After stirring at the same temperature for 30 minutes, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was concentrated under reduced pressure. Add dichloromethane to the resulting residue to remove insoluble matter. After going door to door, I washed it with water. The residue obtained by drying over magnesium sulfate and concentrating the solvent under reduced pressure was purified by silica gel column chromatography (eluent: dichloromethane:methanol-20=1).
エタノール−水より再結晶して、2.1gの8−メチル
−3−[1−ヒドロキシ−1−(2−ピリジル)メチル
]カルボスチリル塩酸塩を得た。Recrystallization from ethanol-water gave 2.1 g of 8-methyl-3-[1-hydroxy-1-(2-pyridyl)methyl]carbostyryl hydrochloride.
mp 250〜270°C(分解)
淡褐色粉末状
NMR(DMSO−d6 )δ;
2、43 (3H,s)
6.11 (IH,s)
7.16 (IH,t、J=6.8Hz)7.39 (
LH,d、J=6.8Hz)7.64 (IH,d、J
=6.8Hz)7.94 (2H,m)
8.20 (IH,s)
8.42 (IH,t、J=7.6Hz)8.79 (
IH,d、J=6.0Hz)11.09 (IH,s)
実施例2
金属マグネシウム0.76gのテトラヒドロフラン1雁
の懸濁液にジブロモブタンを数滴加え、これにジメチル
アミノプロピルクロリド3.8gのテトラヒドロフラン
10111i2溶液を滴下した。更に室温で30分間攪
拌後、この溶液を水冷攪拌下、8−メチル−3−ホルミ
ルカルボスチリル2.0gのテトラヒドロフラン10艦
懸濁液中に滴下した。同温度にて1時間攪拌後、反応液
に飽和塩化アンモニウム水溶液を加え、酢酸エチルによ
り抽出した。水洗及び硫酸マグネシウムにて乾燥後、溶
媒を減圧留去した。得られた残渣をフマール酸塩とし、
エタノール−水より再結晶し、1.6gの8−メチル−
3−(1−ヒドロキシ−4−ジメチルアミノブチル)カ
ルボスチリル・フマル酸塩を得た。mp 250-270°C (decomposition) Pale brown powder NMR (DMSO-d6) δ; 2,43 (3H,s) 6.11 (IH,s) 7.16 (IH,t, J=6.8Hz )7.39 (
LH, d, J = 6.8Hz) 7.64 (IH, d, J
= 6.8Hz) 7.94 (2H, m) 8.20 (IH, s) 8.42 (IH, t, J = 7.6Hz) 8.79 (
IH, d, J = 6.0 Hz) 11.09 (IH, s) Example 2 A few drops of dibromobutane were added to a suspension of 0.76 g of metallic magnesium in 1 g of tetrahydrofuran, and 3. 8 g of tetrahydrofuran 10111i2 solution was added dropwise. After further stirring at room temperature for 30 minutes, this solution was added dropwise to a suspension of 2.0 g of 8-methyl-3-formylcarbostyryl in tetrahydrofuran while stirring and cooling with water. After stirring at the same temperature for 1 hour, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. After washing with water and drying with magnesium sulfate, the solvent was distilled off under reduced pressure. The obtained residue is used as fumarate,
Recrystallized from ethanol-water to give 1.6 g of 8-methyl-
3-(1-hydroxy-4-dimethylaminobutyl)carbostyryl fumarate was obtained.
mp205〜207℃
無色針状
実施例3
ジイソプロピルアミン3疵のテトラヒドロフラン10郵
溶液に、10°C以下にて15%n−ブチルリチウムn
−ヘキサン溶液15軛を滴下する。mp 205-207°C Colorless needles Example 3 15% n-butyllithium n was added to a 10% solution of diisopropylamine in tetrahydrofuran at 10°C or below.
- Add 15 drops of hexane solution.
水冷中にて30分攪拌後、これを−50〜−60°Cに
冷却し、ジメチルアセトアミド2齢を滴下した。同温度
にて1時間攪拌後、この溶液を、−50℃冷却攪拌下に
、8−メチル−3−ホルミルカルボスチリル1.8gの
テトラヒドロフラン10雁懸濁液中に滴下し、徐々に室
温まで上昇させながら2時間攪拌した。反応液を氷水−
酢酸エチルに注ぎ込んで不溶物を炉別した。不溶物を更
に酢酸エチルで洗浄し、先の炉液と合わせて、硫酸マグ
ネシウムで乾燥した。溶媒を減圧濃縮して、1.24g
の8−メチル−3−(1−ヒドロキシ2−ジメチルアミ
ノカルボニルエチル)カルボスチリルを得た。After stirring for 30 minutes under water cooling, this was cooled to -50 to -60°C, and dimethylacetamide 2nd grade was added dropwise. After stirring at the same temperature for 1 hour, this solution was added dropwise to a suspension of 1.8 g of 8-methyl-3-formylcarbostyryl in 10 geese of tetrahydrofuran while cooling and stirring at -50°C, and the temperature was gradually raised to room temperature. The mixture was stirred for 2 hours while stirring. Pour the reaction solution into ice water.
The mixture was poured into ethyl acetate to remove insoluble matter. The insoluble matter was further washed with ethyl acetate, combined with the above-mentioned furnace solution, and dried over magnesium sulfate. Concentrate the solvent under reduced pressure to obtain 1.24g
8-methyl-3-(1-hydroxy-2-dimethylaminocarbonylethyl)carbostyryl was obtained.
NMR(DMSO−ds )δ;
2.48 (3H,s)
2.40〜2. 60 (IH,m)2.82 (
IH,dci、J=2.5Hz15、 0Hz)
2.69 (3H,s)
3、 04 (3H,s)
5、 14 (2H,d、J=7,0Hz)5.41
(LH,brs)
7.14 (IH,t、J=7.5Hz)7.36
(IH,d、J=7.5Hz)7− 59 (IH
,d、 J=7.5Hz)7、 99 (LH,5
)
ICL 98 (IH,brs)
実施例4〜34
なお下記第2表において、各基の前に記されている数字
は、その基の置換位置を示している。NMR (DMSO-ds) δ; 2.48 (3H, s) 2.40-2. 60 (IH, m)2.82 (
IH, dci, J=2.5Hz15, 0Hz) 2.69 (3H,s) 3, 04 (3H,s) 5, 14 (2H,d, J=7,0Hz) 5.41
(LH, brs) 7.14 (IH, t, J=7.5Hz) 7.36
(IH, d, J=7.5Hz) 7-59 (IH
, d, J=7.5Hz) 7, 99 (LH, 5
) ICL 98 (IH, brs) Examples 4 to 34 In Table 2 below, the number written in front of each group indicates the substitution position of that group.
実施例1〜3と同様にして適当な出発原料を用いて以下
の化合物を得た。The following compounds were obtained in the same manner as in Examples 1 to 3 using appropriate starting materials.
6つ
1)NMR(CDCf3) δ; (フリ一体のNM
R)
3.16 (IH,dd、J=8.38Hz。6 1) NMR (CDCf3) δ; (Furi-integrated NM
R) 3.16 (IH, dd, J=8.38Hz.
J=14.8Hz) 3.52 (LH,J=3.04Hz。J=14.8Hz) 3.52 (LH, J = 3.04Hz.
J=14.8Hz)
3.91 (3H,s)
3.94 (3H,s)
5.35 (IH,m)
6.21 (IH,s)
6.78 (IH,s)
6.94 (IH,s)
7.20 (2H,dd、J=7〜8HzJ=1〜2
Hz)
7.59 (LH,dt、J=1〜2HzJ=7〜3
Hz)
7.87 (IH,s)
8、 54 (IH,m)
11、 36 (LH,s)
2)NMR(DMSO−ds ) δ ;1、 26
(6H,t、 J=6. 5Hz)1.80〜2
. 18 (2H,m)2、 92〜3. 52
(9H,m)3、 57〜3.80 (IH,m)5
.49〜5. 56 (IH,m)7、 29 (
IH,t、 J=7. 0Hz)7.42 (IH
,d、 J=7. 0Hz)7、 56 (IH,
t、 J=’7.0Hz)7.89〜8. 12
(3H,m)8、 5:3 (IH,t、 J=7
. 0Hz)8.84 (IH,d、 J=5゜
0Hz)10、 50 (LH,brs)
12、 10 (LH,brs)
3)NMR(DMSO−ds ) δ ;1、 35
(9H,s)
1、 81〜2. 17 (2H,m)2、 89−
3.44 (6H,m)3. 52〜3. 90
(IH,m)5、 30〜5. 71 (IH,m)
7、30 (IH,t、 J=7. 5Hz)7.
41 (LH,d、 J=7. 5Hz)7、 5
9 (IH,t、 J=7. 5Hz)7、 73
〜8. 29 (3H,m)8、 39〜8. 51
(IH,m)8、 55〜8. 99 (2H,
m、)12、 12 (IH,brs)
4)NMR(DMSO−ds ) δ;2.4B
(3H2s)
6、 11 (IH,s)
7、 16 (IH,t、 J=6.8Hz)7.
39 (IH,d、 J=6.8Hz)7.64
(LH,d、 J=6.8Hz)7、 91 (
2H,m)
8、 20 (IH,s)
8.42 (IH,t、 J=7゜ 6Hz)8.
79 (IH,d、 J=6.0Hz)11.09
(IH,s)
5)NMR(DMSO−ds )6 ;2.47 (
3H,s)
3.25 (LH,dd、 Ja=8.4J b=
15Hz)
3.68 (IH,dd、J−3,0Hz。J=14.8Hz) 3.91 (3H,s) 3.94 (3H,s) 5.35 (IH,m) 6.21 (IH,s) 6.78 (IH,s) 6.94 ( IH, s) 7.20 (2H, dd, J=7~8HzJ=1~2
Hz) 7.59 (LH, dt, J=1~2HzJ=7~3
Hz) 7.87 (IH, s) 8, 54 (IH, m) 11, 36 (LH, s) 2) NMR (DMSO-ds) δ; 1, 26
(6H, t, J=6.5Hz) 1.80~2
.. 18 (2H, m)2, 92-3. 52
(9H, m)3, 57-3.80 (IH, m)5
.. 49-5. 56 (IH, m)7, 29 (
IH,t, J=7. 0Hz) 7.42 (IH
, d, J=7. 0Hz) 7, 56 (IH,
t, J='7.0Hz)7.89~8. 12
(3H, m)8, 5:3 (IH,t, J=7
.. 0Hz) 8.84 (IH, d, J=5°
0Hz) 10, 50 (LH, brs) 12, 10 (LH, brs) 3) NMR (DMSO-ds) δ; 1, 35
(9H, s) 1, 81-2. 17 (2H, m)2, 89-
3.44 (6H, m)3. 52-3. 90
(IH, m)5, 30-5. 71 (IH, m)
7, 30 (IH, t, J=7.5Hz)7.
41 (LH, d, J=7.5Hz)7, 5
9 (IH, t, J=7.5Hz)7, 73
~8. 29 (3H, m)8, 39-8. 51
(IH, m) 8, 55-8. 99 (2H,
m, ) 12, 12 (IH, brs) 4) NMR (DMSO-ds) δ; 2.4B
(3H2s) 6, 11 (IH,s) 7, 16 (IH,t, J=6.8Hz)7.
39 (IH, d, J=6.8Hz)7.64
(LH, d, J=6.8Hz)7, 91 (
2H, m) 8, 20 (IH, s) 8.42 (IH, t, J=7° 6Hz)8.
79 (IH, d, J=6.0Hz) 11.09
(IH,s) 5) NMR (DMSO-ds)6;2.47 (
3H, s) 3.25 (LH, dd, Ja=8.4J b=
15Hz) 3.68 (IH, dd, J-3,0Hz.
J−15Hz)
4.48 (3H,s)
5、 10〜5. 20 (IH,m)5.90
(IH,d、J 〜3〜4Hz)7、 16 (IH
,t、 J=6Hz)7、 39 (LH,d、
J=6Hz)7、 62 (IH,d、 J=6
Hz)7、 90〜8. 10 (3H,m)8、
52 (IH,t、 J=6Hz)9.02 (
IH,d、 J=6Hz)11、 15 (IH,
s)
6)NMR(CDCI!、a ) δ; (フリ一体の
NMR)
1、 11 (9H,s)
2、 46 (3H,s)
2、 68 (IH,dd、 J=8.4Hz。J-15Hz) 4.48 (3H, s) 5, 10-5. 20 (IH, m)5.90
(IH, d, J ~3~4Hz) 7, 16 (IH
,t, J=6Hz)7, 39 (LH,d,
J=6Hz)7, 62 (IH,d, J=6
Hz) 7, 90-8. 10 (3H, m)8,
52 (IH, t, J=6Hz)9.02 (
IH, d, J=6Hz) 11, 15 (IH,
s) 6) NMR (CDCI!, a) δ; (Free NMR) 1, 11 (9H, s) 2, 46 (3H, s) 2, 68 (IH, dd, J=8.4Hz.
J=15Hz) 3− 16 (IH,dd、 J=3Hz。J=15Hz) 3-16 (IH, dd, J=3Hz.
J=15Hz)
4、 83 (IH,m)
7、 13 (IH,t、 J=7.6Hz)7、
31 (IH,d、 J=7. 6Hz)7.4
7 (IH,d、 J=7.6Hz)7、 94
(IH,s)
7)NMR(CDCJa ) δ; (フリ一体のN
MR)
2、 31 (3H,s)
2、 30〜2. 65 (9H,m)2、 7C1
−3,0(IH,broad s )3.01 (L
H,dd、 J=3Hz。J=15Hz) 4, 83 (IH, m) 7, 13 (IH, t, J=7.6Hz) 7,
31 (IH, d, J=7.6Hz)7.4
7 (IH, d, J=7.6Hz) 7, 94
(IH, s) 7) NMR (CDCJa) δ;
MR) 2, 31 (3H,s) 2, 30-2. 65 (9H, m)2, 7C1
-3,0 (IH, broad s ) 3.01 (L
H, dd, J=3Hz.
J=15Hz) 4、 24 (IH,s) 5.01 (LH,dd、J−3Hz。J=15Hz) 4, 24 (IH, s) 5.01 (LH, dd, J-3Hz.
J =8Hz)
7、 12 (IH,t、 J=7.6Hz)7.
31 (IH,d、J=7.6Hz)7.45 (
IH,d、 J=7.6Hz)8.01 (IH,
s)
9.62 (1’H,s)
8)NMR(DMS O−d6); δ2.48 (
3H,s)
2.40〜2.60 (LH,m)
2.82 (IH,dd、 J=2.5Hz。J=8Hz) 7, 12 (IH, t, J=7.6Hz)7.
31 (IH, d, J=7.6Hz) 7.45 (
IH, d, J=7.6Hz) 8.01 (IH,
s) 9.62 (1'H, s) 8) NMR (DMS O-d6); δ2.48 (
3H, s) 2.40-2.60 (LH, m) 2.82 (IH, dd, J=2.5Hz.
J=15. 0Hz)
2、 69 (3H,s)
3、 04 (3H,s)
5.14 (2H,d、J=7.0Hz)5.41
(IH,brs)
7.14 (IH,t、J=7.5Hz)7.36
(IH,d、J=7.5Hz)7.59 (LH,
d、J=7.5Hz)7.99 (IH,5)
10.98 (LH,brs)
9)NMR(CDCJ3) δ;
1.80〜2゜29 (2H,m)
2.79〜3.11 (2H,m)
3.39 (IH,dd、J=6.0Hz。J=15. 0Hz) 2, 69 (3H, s) 3, 04 (3H, s) 5.14 (2H, d, J=7.0Hz) 5.41
(IH, brs) 7.14 (IH, t, J=7.5Hz) 7.36
(IH, d, J=7.5Hz) 7.59 (LH,
d, J=7.5Hz) 7.99 (IH, 5) 10.98 (LH, brs) 9) NMR (CDCJ3) δ; 1.80-2°29 (2H, m) 2.79-3. 11 (2H, m) 3.39 (IH, dd, J=6.0Hz.
J−13゜5Hz)
訊52〜3.79 (3H,m)
5.36〜5.60 (IH,m)
5.97 (IH,d、J=10.0Hz)6.97−
7.38 (3H,m)
7.39−7.67 (3H,m)
乙79 (IH,d、 J=8.0Hz)8、 56
(IH,d、 J=4. 0Hz)12、 8
(IH,brs)
実施例35
8−メチル−3−[1−ヒドロキシ−2−(2−ピリジ
ル)エチル]カルボスチリル4.0gのジクロロメタン
40m!溶液にヨウ化メチル5w2を加え、封管中90
〜100°Cにて5時間加熱攪拌した。反応終了後、析
出した結晶を枦取し、ジクロロメタンにて洗浄し、乾燥
した。エタノール水よ゛り再結晶して、4.7gの2−
[2−ヒドロキシ−2−(8−メチルカルボスチリル−
3−イル)エチル]−1−メチルピリジニウムアイオダ
イドを得た。J-13゜5Hz) 52~3.79 (3H, m) 5.36~5.60 (IH, m) 5.97 (IH, d, J=10.0Hz) 6.97-
7.38 (3H, m) 7.39-7.67 (3H, m) Otsu 79 (IH, d, J=8.0Hz) 8, 56
(IH, d, J=4.0Hz) 12, 8
(IH, brs) Example 35 4.0 g of 8-methyl-3-[1-hydroxy-2-(2-pyridyl)ethyl]carbostyryl in 40 m of dichloromethane! Add methyl iodide 5w2 to the solution and add 90% methyl iodide in a sealed tube.
The mixture was heated and stirred at ~100°C for 5 hours. After the reaction was completed, the precipitated crystals were collected, washed with dichloromethane, and dried. Recrystallize from ethanol and water to obtain 4.7 g of 2-
[2-Hydroxy-2-(8-methylcarbostyryl-
3-yl)ethyl]-1-methylpyridinium iodide was obtained.
mp 265−275°C(分解) 黄色プリズム状 NMR(DMSO−66)δ 2.47 (3H,s) 3、 25 (IH,dd、 J=8.4Hz。mp 265-275°C (decomposition) yellow prismatic NMR (DMSO-66)δ 2.47 (3H, s) 3, 25 (IH, dd, J = 8.4Hz.
J=15Hz) 3、 68 (IH,dd、 J−3,0Hz。J=15Hz) 3, 68 (IH, dd, J-3,0Hz.
J=15Hz)
4.48 (3H,s)
5、 10〜5.20 (LH,m’)5.90
(IH,d、 J=3〜4Hz)7、 16 (I
H,t、 J=6Hz)7.39 (IH,d、
J=6Hz)7、 62 (IH,d、 J=6
Hz)7、 90〜8. 10 (3H,m)8、
52 (IH,t、 J=6Hz)9.02 (
IH,d、J =6Hz)11、 15 (IH,s
)
実施例36
8−メチル−3−オキシラニルカルボスチリル0.50
gをアセトニトリル20加に溶解し、を−ブチルアミン
5雁を加え、8時間加熱還流した。J=15Hz) 4.48 (3H, s) 5, 10~5.20 (LH, m') 5.90
(IH, d, J=3~4Hz)7, 16 (I
H, t, J=6Hz) 7.39 (IH, d,
J=6Hz)7, 62 (IH,d, J=6
Hz) 7, 90-8. 10 (3H, m)8,
52 (IH, t, J=6Hz)9.02 (
IH, d, J = 6Hz) 11, 15 (IH, s
) Example 36 8-methyl-3-oxiranylcarbostyryl 0.50
The solution was dissolved in 20 g of acetonitrile, 5 g of butylamine was added thereto, and the mixture was heated under reflux for 8 hours.
反応液に水を加え、ジクロロメタンにて抽出した。Water was added to the reaction solution, and the mixture was extracted with dichloromethane.
水洗及び硫酸マグネシウム乾燥の後、溶媒を減圧濃縮し
た。得られた残渣にジクロロメタン−ジエチルエーテル
を加え、析出晶を枦取し、ジクロロメタン−ジエチルエ
ーテルにて洗浄し、乾燥した。After washing with water and drying magnesium sulfate, the solvent was concentrated under reduced pressure. Dichloromethane-diethyl ether was added to the resulting residue, and the precipitated crystals were collected, washed with dichloromethane-diethyl ether, and dried.
塩酸塩とした後、エタノール−ジエチルエーテルより再
結晶して、0.20gの8−メチル−(1−ヒドロキシ
−2−t−ブチルアミノエチル)カルボスチリル塩酸塩
を得た。After converting it into a hydrochloride, it was recrystallized from ethanol-diethyl ether to obtain 0.20 g of 8-methyl-(1-hydroxy-2-t-butylaminoethyl)carbostyryl hydrochloride.
mp 255〜262°C(分解)
白色粉末状
実施例36と同様にして前記実施例18.21及び22
の化合物を得た。mp 255-262°C (decomposition) White powder Preparation of Examples 18, 21 and 22 in the same manner as Example 36
The compound was obtained.
実施例37
水素化アルミニウムリチウム0.30gのテトラヒドロ
フラン20軛懸濁液に8−メチル−3(1−ヒドロキシ
−2−ジメチルアミノカルボニルエチル)カルボスチリ
ル1.25gを加え、室温で2時間攪拌した。水冷下、
反応液に飽和硫酸ナトリウムを加え、室温で1時間攪拌
後、ハイフロス−パーセルを通して、濾過し、沈殿物を
テトラヒドロフランにて洗浄後、硫酸マグネシウムにて
乾燥した。溶媒を減圧濃縮して得られた残渣をフマール
酸塩とし、エタノール−水より再結晶して、0.26g
の8−メチル−3−(1−ヒドロキシ−3−ジメチルア
ミノプロピル)カルボスチリル1/2フマール酸塩を得
た。Example 37 1.25 g of 8-methyl-3(1-hydroxy-2-dimethylaminocarbonylethyl)carbostyryl was added to a suspension of 0.30 g of lithium aluminum hydride in 20 yoke of tetrahydrofuran, and the mixture was stirred at room temperature for 2 hours. Under water cooling,
Saturated sodium sulfate was added to the reaction solution, and after stirring at room temperature for 1 hour, it was filtered through Hyfloth-Parcel, and the precipitate was washed with tetrahydrofuran and dried over magnesium sulfate. The residue obtained by concentrating the solvent under reduced pressure was converted into a fumarate salt, which was recrystallized from ethanol-water to give 0.26 g.
8-methyl-3-(1-hydroxy-3-dimethylaminopropyl)carbostyryl 1/2 fumarate was obtained.
mp 212〜214°C
淡黄色粉末状
実施例37と同様にして適当な出発原料を用いて前記実
施例18.20及び21の化合物を得た。mp 212-214°C Pale yellow powder Compounds of Examples 18, 20 and 21 were obtained in the same manner as in Example 37 using appropriate starting materials.
実施例38
8−メチル−3−[1−ヒドロキシ−2−(2ピリジル
)エチル]カルボスチリル0.5gをピリジン5雁に溶
かし、無水酢酸0゜84Tnf2を加え、70℃で1時
間加熱攪拌した。反応液を氷水中にあけ、折用結晶をi
1取し、水洗し、乾燥した。Example 38 0.5 g of 8-methyl-3-[1-hydroxy-2-(2pyridyl)ethyl]carbostyryl was dissolved in pyridine, 0°84Tnf2 of acetic anhydride was added, and the mixture was heated and stirred at 70°C for 1 hour. . Pour the reaction solution into ice water and fold the folded crystals into
One portion was taken, washed with water, and dried.
蓚酸塩とし、エタノール−n−ヘキサンより再結晶して
、0.427gの8−メチル−3−[1アセチルオキシ
−2−(2−ピリジル)エチル]カルボスチリル・蓚酸
塩を得た。The oxalate was recrystallized from ethanol-n-hexane to obtain 0.427 g of 8-methyl-3-[1acetyloxy-2-(2-pyridyl)ethyl]carbostyryl oxalate.
mp 137〜141°C(分解) 黄色粉末状 NMR(DMSO−ds );δ 2.02 (3H,s) 2.45 (3H,s) 3.19 (IH,dd、J=8.5Hz。mp 137-141°C (decomposition) yellow powder NMR (DMSO-ds); δ 2.02 (3H, s) 2.45 (3H, s) 3.19 (IH, dd, J=8.5Hz.
J=14.0Hz) 3.44 (IH,dd、J=4.0Hz。J=14.0Hz) 3.44 (IH, dd, J=4.0Hz.
J=14− 0Hz) 6.32 (IH,dd、J=4.0Hz。J=14-0Hz) 6.32 (IH, dd, J=4.0Hz.
J=8.5Hz)
7.12 (LH,t、J=7.5Hz)7.20〜7
.42 (3H,m)
7.55 (LH,d、J=7.5Hz)7、 75
(IH,t、 J=7. 5Hz)7、 84
(IH,s)
8、 51 (LH,d、 J=4. 0Hz)1
1、 10 (IH,brs)
実施例3つ
5%Pd−C0,1gのエタノール10配懸濁液に8−
メチル−3−[1−アセチルオキシ2−(2−ピリジル
)エチル]カルボスチリル・蓚酸塩0.63.gを加え
、水素圧1気圧、50°Cにて水素添加した。触媒を炉
別後、7戸液を減圧濃縮した。得られた残渣を塩酸塩と
し、エタノールジエチルエーテルより再結晶して、8−
メチル:3− [:2− (2−ピリジル)エチル]カ
ルボスチリル・塩酸塩0.38gを得た。J=8.5Hz) 7.12 (LH, t, J=7.5Hz)7.20~7
.. 42 (3H, m) 7.55 (LH, d, J=7.5Hz) 7, 75
(IH, t, J=7.5Hz) 7, 84
(IH, s) 8, 51 (LH, d, J=4.0Hz) 1
1, 10 (IH, brs) Three Examples 8-
Methyl-3-[1-acetyloxy2-(2-pyridyl)ethyl]carbostyryl oxalate 0.63. g was added thereto, and hydrogenation was carried out at 50°C under a hydrogen pressure of 1 atm. After the catalyst was separated from the furnace, the seven door liquid was concentrated under reduced pressure. The resulting residue was converted into a hydrochloride and recrystallized from ethanol diethyl ether to give 8-
0.38 g of methyl:3-[:2-(2-pyridyl)ethyl]carbostyryl hydrochloride was obtained.
mp 205〜209°C(分解)
無色針状
」二記化合物のフリ一体NMR(CDCf3);δ
2.49 (3H,s)
3.05〜3.30 (4H,m)
7.05〜7.40 (5H,m)
7.60 (2H,m)
8.56 (IH,d、J=’6〜7Hz)9.73
(LH,brs)
実施例40
60%水素化ナトリウム0.143gをテトラヒドロフ
ラン25軛に懸濁し、アルゴン気流下水冷攪拌下に8−
メチル−3−[1−ヒドロキシ2−(2−ピリジル)エ
チルコヵルボスチリル1.0gを加え、室温で30分間
攪拌した。これを−40°Cに冷却し、1.54Mn−
ブチルリチウムn−ヘキサン溶液2. 32n[を滴下
し、同温で30分間攪拌した後、ヨウ化メチル0.60
8gのテトラヒドロフラン5証溶液を滴下し、温度を徐
々に上げ、o′cにて48時間攪拌した。飽和塩化アン
モニウム水溶液を加え、反応液を減圧濃縮し、水を加え
、塩化メチレンで抽出した。有機層を飽和塩化ナトリウ
ム水溶液で洗浄し、硫酸ナトリウムで乾燥した。溶媒留
去後、残渣をシリカゲルカラムクロマトグラフィー(溶
出液・四塩化炭素二アセトニトリル−5=1)により精
製した。フマール酸塩とし、エタノール−nヘキサンよ
り再結晶して、0.505gの8メチル−3−[1−メ
トキシ−2−(2−ピリジル)エチル]カルボスチリル
・フマール酸塩を得た。mp 205-209°C (decomposition) Free integral NMR (CDCf3) of colorless acicular compound (CDCf3); δ 2.49 (3H, s) 3.05-3.30 (4H, m) 7.05-7 .40 (5H, m) 7.60 (2H, m) 8.56 (IH, d, J='6~7Hz) 9.73
(LH, brs) Example 40 0.143 g of 60% sodium hydride was suspended in 25 yoke of tetrahydrofuran, and 8-
1.0 g of methyl-3-[1-hydroxy 2-(2-pyridyl)ethylcocarbostyryl was added, and the mixture was stirred at room temperature for 30 minutes. This was cooled to -40°C and 1.54Mn-
Butyllithium n-hexane solution 2. After dropping 32n of methyl iodide and stirring at the same temperature for 30 minutes,
8 g of tetrahydrofuran solution was added dropwise, the temperature was gradually raised, and the mixture was stirred at o'c for 48 hours. A saturated aqueous ammonium chloride solution was added, the reaction mixture was concentrated under reduced pressure, water was added, and the mixture was extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution and dried over sodium sulfate. After evaporation of the solvent, the residue was purified by silica gel column chromatography (eluent: carbon tetrachloride diacetonitrile-5=1). The fumarate was recrystallized from ethanol-n-hexane to obtain 0.505 g of 8methyl-3-[1-methoxy-2-(2-pyridyl)ethyl]carbostyryl fumarate.
mp 182〜184°C(分解)
無色針状
実施例41
8−メチル−3−[1−ヒドロキシ−2−(2ピリジル
)エチル]カルボスチリル1.0gをジメチルスルホキ
シド5維に溶かし、無水酢酸2加を滴下し、室温で20
時間攪拌した。反応液を氷水中にあけ、析出結晶を枦取
し、水洗し、乾燥した。これを塩酸塩とし、エタノール
より再結晶して、0.35gの8−メチル−3−[2’
−(2ピリジル)アセチル]カルボスチリル・塩酸塩を
得た。mp 182-184°C (decomposition) Colorless needle Example 41 Dissolve 1.0 g of 8-methyl-3-[1-hydroxy-2-(2pyridyl)ethyl]carbostyryl in 5 fibers of dimethyl sulfoxide, and dissolve 2 acetic anhydride. Add it dropwise and let it stand for 20 minutes at room temperature.
Stir for hours. The reaction solution was poured into ice water, and the precipitated crystals were collected, washed with water, and dried. This was made into a hydrochloride salt, recrystallized from ethanol, and 0.35 g of 8-methyl-3-[2'
-(2pyridyl)acetyl]carbostyryl hydrochloride was obtained.
mp 260〜263°C(分解)
黄色粉末状
実施例42
0.4gの8−メチル−3−[1−ヒドロキシ2−(5
−メトキシ−2−ピリジル)エチル]カルボスチリル及
び49%臭化水素酸5m!を]00℃にて3時間加熱反
応させた。反応液を冷却後、析出品を枦取し、メタノー
ルより再結晶して、0.3gの8−メチル−3−[2−
(5−メトキシ−2−ピリジル)−1−ビニル]カルボ
スチリルを得た。mp 260-263°C (decomposition) Yellow powder Example 42 0.4 g of 8-methyl-3-[1-hydroxy 2-(5
-methoxy-2-pyridyl)ethyl]carbostyryl and 49% hydrobromic acid 5m! ] A heating reaction was carried out at 00°C for 3 hours. After cooling the reaction solution, the precipitate was collected and recrystallized from methanol to give 0.3 g of 8-methyl-3-[2-
(5-methoxy-2-pyridyl)-1-vinyl]carbostyryl was obtained.
mp 215〜223°C
黄色プリズム状
NMR(CDCJ:a ):δ
2.48 (3H,s)
3.88 (3H,s)
7.10〜7.50 (5H,m)
7、 74 (2H,ABq、 J=20Hz)7
、 92 (IH,s)
8、 32 (LH,d、 J=2〜3Hz)9、
05 (IH,s)
実施例43
酸化白金0.1gをメタノール70m2に懸濁し、8−
メチル−3−[1−ヒドロキシ−2−(2−ピリジル)
エチル]カルボスチリル1.0g及び濃塩酸0. 59
m!を加え、50℃、水素圧4気圧にて接触還元した。mp 215-223°C Yellow prismatic NMR (CDCJ:a): δ 2.48 (3H, s) 3.88 (3H, s) 7.10-7.50 (5H, m) 7, 74 (2H , ABq, J=20Hz)7
, 92 (IH, s) 8, 32 (LH, d, J=2~3Hz) 9,
05 (IH,s) Example 43 0.1 g of platinum oxide was suspended in 70 m2 of methanol, and 8-
Methyl-3-[1-hydroxy-2-(2-pyridyl)
ethyl]carbostyril 1.0g and concentrated hydrochloric acid 0. 59
m! was added, and catalytic reduction was carried out at 50°C and 4 atmospheres of hydrogen pressure.
水素の吸収停止後触媒を濾過し、炉液を減圧下に濃縮乾
固した。残渣に水を加え、10%水酸化ナトリウム水溶
液でpH=10にした後ジクロロメタンで抽出し、有機
層を水洗し、硫酸すトリウムで乾燥した。溶媒留去後、
残渣をシリカゲルカラムクロマトグラフィー(溶出液;
塩化メチレン:メタノール−10=1→塩化メチレン:
メタノール:アンモニア−10:1:0.1)により精
製した。これを塩酸塩とし、エタノール−ジエチルエー
テルより再結晶して、8メチル−3−[1−ヒドロキシ
−2−(2−ピペリジニル)エチル]カルボスチリル・
塩酸塩0.32gを得た。After hydrogen absorption had stopped, the catalyst was filtered, and the furnace liquid was concentrated to dryness under reduced pressure. Water was added to the residue, the pH was adjusted to 10 with a 10% aqueous sodium hydroxide solution, and the mixture was extracted with dichloromethane. The organic layer was washed with water and dried over sodium sulfate. After distilling off the solvent,
The residue was subjected to silica gel column chromatography (eluent;
Methylene chloride: methanol - 10 = 1 → methylene chloride:
Methanol:ammonia-10:1:0.1). This was converted into a hydrochloride, recrystallized from ethanol-diethyl ether, and 8methyl-3-[1-hydroxy-2-(2-piperidinyl)ethyl]carbostyryl.
0.32 g of hydrochloride was obtained.
mp 256.0〜256.5°C(分解)白色粉末
状
実施例44
酸化白金0.]、gをメタノール100維に懸濁し、2
’−[2−(8−メチルカルボスチリル−3イル)−2
−ヒドロキシエチルヨー1−メチルピリジニウム・アイ
オダイド1.0gを加え、50°C1水素圧4気圧にて
接触還元した。水素の吸収停止後、触媒を濾過し、炉液
を減圧下に濃縮乾固した。残渣に水を加え、10%水酸
化ナトリウム水溶液でpH=10にした後、ジクロロメ
タンにて抽出し、有機層を水洗し、硫酸ナトリウムで乾
燥した。溶媒留去後塩酸塩とし、エタノールジエチルエ
ーテルより再結晶して、0.34gの8−メチル−3−
[2−(1−メチル−2−ピペリジニル)−1,−ヒド
ロキシエチル]カルボスチリル・塩酸塩を得た。mp 256.0-256.5°C (decomposition) White powder Example 44 Platinum oxide 0. ], g was suspended in 100 fibers of methanol, 2
'-[2-(8-methylcarbostyryl-3yl)-2
-Hydroxyethylio1-methylpyridinium iodide (1.0 g) was added, and catalytic reduction was carried out at 50°C and 4 atmospheres of hydrogen pressure. After hydrogen absorption had stopped, the catalyst was filtered, and the furnace liquid was concentrated to dryness under reduced pressure. Water was added to the residue, the pH was adjusted to 10 with a 10% aqueous sodium hydroxide solution, and the mixture was extracted with dichloromethane. The organic layer was washed with water and dried over sodium sulfate. After distilling off the solvent, it was converted into a hydrochloride salt and recrystallized from ethanol diethyl ether to give 0.34 g of 8-methyl-3-
[2-(1-methyl-2-piperidinyl)-1,-hydroxyethyl]carbostyryl hydrochloride was obtained.
mp 254.5〜255°C(分解)白色粉末状
実施例45
4−(3−クロロプロピル) −3−[1−ヒドロキシ
−2−(ピリジル)エチル]カルボスチリル1.0gを
アセトニトリル20T119に溶かし、ジエチルアミン
0.60誰、ヨウ化ナトリウム0.44g及び炭酸カリ
ウム0.44gを加え。mp 254.5-255°C (decomposition) White powder Example 45 Dissolve 1.0 g of 4-(3-chloropropyl)-3-[1-hydroxy-2-(pyridyl)ethyl]carbostyryl in acetonitrile 20T119. , 0.60 g of diethylamine, 0.44 g of sodium iodide and 0.44 g of potassium carbonate were added.
10時間加熱還流した。反応液を減圧濃縮し、水を加え
、ジクロロメタンで抽出し、有機層を水洗し、硫酸すト
リウムで乾燥した。溶媒留去後、残渣をシリカゲルカラ
ムクロマトグラフィー(溶出液;塩化メチレン:メタノ
ール−20=1−塩化メチレン:メタノール:アンモニ
ア−10:1:0.1)により精製した。塩酸塩とし、
エタノール−ジエチルエーテルより再結晶して、0.7
6gの4−(3−ジエチルアミノプロビル)−3[1−
ヒドロキシ−2−(2−ピリジル)エチル]カルボスチ
リル・2塩酸塩を得た。The mixture was heated under reflux for 10 hours. The reaction solution was concentrated under reduced pressure, water was added, and extraction was performed with dichloromethane. The organic layer was washed with water and dried over sodium sulfate. After distilling off the solvent, the residue was purified by silica gel column chromatography (eluent; methylene chloride:methanol-20=1-methylene chloride:methanol:ammonia-10:1:0.1). As hydrochloride,
Recrystallized from ethanol-diethyl ether to give 0.7
6 g of 4-(3-diethylaminopropyl)-3[1-
Hydroxy-2-(2-pyridyl)ethyl]carbostyryl dihydrochloride was obtained.
mp 1.44〜148°C(分解)淡黄色粉末状
実施例45と同様にして、適当な出発原料を用いて前記
実施例14及び15の化合物を得た。mp 1.44-148°C (decomposed) Pale yellow powder Compounds of Examples 14 and 15 were obtained in the same manner as in Example 45 using appropriate starting materials.
薬理試験例
手間等[C1rc 、 Res、 、第48巻、第51
0518頁(1980年)]が、イヌ心室筋に用いた方
法に準じて、この試験を行なった。Pharmacology test examples and effort [C1rc, Res, Vol. 48, No. 51
0518 (1980)] used for canine ventricular myocardium.
即ち、ネコ(体重1.5〜5kg)をケタミン30■/
kgの筋肉内注射とベンドパルビタール20mg/kg
の腹腔内投与により麻酔した後、心臓を冷やしたタイロ
ード液[NaC−1213アミルモル、NaHcO31
5,9ミリモル、グルコース5.5ミリモル、MgCl
21.0ミリモル、NaH2PO40,42ミリモル、
KCffi2.7ミリモル及びCaCl21.8ミリモ
ル]中に摘出した。常法に従い右心室の乳頭筋を摘出し
、タイロード液で満たしたマグナス装置に吊した。タイ
ロード液を酸素95%及び二酸化炭素5%の混合ガスで
曝気し、温度37℃に維持した。That is, a cat (weight 1.5-5 kg) was administered ketamine 30 μ/
kg intramuscular injection and bendoparbital 20 mg/kg
After being anesthetized by intraperitoneal administration of
5.9 mmol, glucose 5.5 mmol, MgCl
21.0 mmol, NaH2PO40.42 mmol,
KCffi 2.7 mmol and CaCl 21.8 mmol]. The papillary muscle of the right ventricle was removed according to a conventional method and suspended in a Magnus device filled with Tyrode's solution. The Tyrode solution was aerated with a gas mixture of 95% oxygen and 5% carbon dioxide and maintained at a temperature of 37°C.
静止張力は0.5kgに合わせた。0.5Hzの頻度で
電気刺激を加えながら、約30分間標本の安定化を図っ
た。刺激を止め、タイロード液をにフリーのタイロード
液で置換した。その30分後、K及びCaフリーのタイ
ロード液に置換し、更に30分後、Kフリー且つCa(
3,6ミリモル)のタイロード液で置換した。1.0分
後より5分毎に刺激間隔320 m5ecで10回トレ
イン刺激を与えると、約半数例で刺激停止後に後収縮が
認められた。電気刺激による収縮及び後収縮が一定した
後、供試化合物を20分間隔で累積的に投与し、10回
目の収縮(第2表中「LCx」として示す)及び1回目
の後収縮(第2表中rA−1”Jとして示す)に対する
作用を検討した。The rest tension was adjusted to 0.5 kg. The specimen was stabilized for approximately 30 minutes while applying electrical stimulation at a frequency of 0.5 Hz. Stimulation was stopped and Tyrode's solution was replaced with free Tyrode's solution. After 30 minutes, it was replaced with K- and Ca-free Tyrode's solution, and after another 30 minutes, it was replaced with K-free and Ca-free Tyrode's solution.
3.6 mmol) of Tyrode's solution. After 1.0 minutes, train stimulation was applied 10 times at a stimulation interval of 320 m5ec every 5 minutes, and after-contraction was observed after the stimulation stopped in about half of the cases. After the electrical stimulation-induced contractions and after-contractions became constant, the test compound was administered cumulatively at 20-minute intervals, and the 10th contraction (indicated as "LCx" in Table 2) and the 1st after-contraction (the second The effect on rA-1''J in the table was investigated.
供試化合物として、下記各化合物を用いた。得られた結
果を第2表に示す。The following compounds were used as test compounds. The results obtained are shown in Table 2.
く供試化合物〉
1.8−メチル−3−[1−ヒドロキシ−2(2−ピリ
ジル)エチル]カルボスチリル第2表
5mg
製剤例1
3−[2−(2−ピリジル)−1
ヒドロキシエチル]−8−メチ
ルカルボスチリル
デンプン
マグネシウムステアレート
乳糖
32mg
8mg
5mg
計 200mg常法に
より1錠中、上記組成物の錠剤を製造した。Test compound> 1.8-Methyl-3-[1-hydroxy-2(2-pyridyl)ethyl]carbostyril Table 2 5 mg Formulation example 1 3-[2-(2-pyridyl)-1 hydroxyethyl] -8-Methylcarbostyryl starch Magnesium stearate Lactose 32 mg 8 mg 5 mg Total 200 mg Tablets of the above composition in one tablet were manufactured by a conventional method.
製剤例2
3− [2−(2−ピリジル) −1500mgヒドロ
キシエチル]−8−メチ
ルカルボスチリル
ポリエチレングリコール 0.3g(分子量:
4000)
塩化ナトリウム 0.9gポリオキシ
エチレンソルビタンモ 0.4gノオレート
メタ重亜硫酸ナトリウム 0.1gメチル−パ
ラベン 0. 18gプロピル−パラベ
ン 0.02g注射用蒸留水
100加上記パラベン類、メタ重亜硫酸ナトリ
ウム及び塩化すトリウムを攪拌しながら80°Cで」1
記の蒸留水に溶解した。得られた溶液を40°Cまで冷
却し、本発明化合物、次にポリエチレングリコール及び
オキシエチレンソルビタンモノオレエートをその溶液中
に溶解した。次のその溶液に注射用蒸留水を加えて最終
の容量に調製し、適当なフィルターペーパーを用いて滅
菌?濾過することにより滅菌して1雁ずつアンプルに分
注し、注射剤を調製した。Formulation example 2 3-[2-(2-pyridyl)-1500mg hydroxyethyl]-8-methylcarbostyryl polyethylene glycol 0.3g (molecular weight:
4000) Sodium chloride 0.9g Polyoxyethylene sorbitan 0.4g Sodium metabisulfite 0.1g Methyl-paraben 0. 18g Propyl-paraben 0.02g Distilled water for injection
100% addition of the above parabens, sodium metabisulfite and thorium chloride at 80°C with stirring.
Dissolved in distilled water. The resulting solution was cooled to 40°C and the compound of the invention, followed by polyethylene glycol and oxyethylene sorbitan monooleate, were dissolved into the solution. Next, add distilled water for injection to the solution to make it to the final volume, and sterilize it using a suitable filter paper. The mixture was sterilized by filtration and dispensed into ampoules one by one to prepare an injection.
(以 上)(that's all)
Claims (1)
シ基、基▲数式、化学式、表等があります▼(R^3^
a及びR^3^bは同一又は異なって、水素原子又は低
級アルキル基を示す。またR^3^a及びR^3^bは
結合する窒素原子と共に、窒素原子又は酸素原子を介し
又は介さず5〜6員環の飽和複素環を形成してもよい。 )を有する低級アルキル基又はハロゲン原子置換低級ア
ルキル基を示す。Aは基 ▲数式、化学式、表等があります▼(R^2は水酸基、
低級アルコキシ基又は低級アルカノイルオキシ基を示す
。)、基−CH=CH−、又は基▲数式、化学式、表等
があります▼を示す。Oは1又は2を示す。Bは低級ア
ルキレン基を示す。R^1は、置換基として、低級アル
キル基、低級アルコキシ基及び置換基として低級アルキ
ル基を有することのあるアミノ基からなる群より選ばれ
た基を1〜3個有することのあるピリジル基、置換基と
して低級アルキル基を有することのあるピペリジニル基
、ピラジル基又は基 ▲数式、化学式、表等があります▼(R^3及びR^4
は 同一又は異なって、水素原子又は低級アルキル基を示す
。またR^3及びR^4は結合する窒素原子と共に窒素
原子又は酸素原子を介し又は介さず5〜6員環の飽和複
素環を形成してもよい。該複素環には置換基として低級
アルキル基が置換してもよい。)を示す。l、m及びn
はそれぞれ0又は1を示す。但し、l+mは0であって
はならない。更に、Aが ▲数式、化学式、表等があります▼を示すとき、mは1
を示すものとする。 カルボスチリル骨格の3、4位の結合は、一重結合又は
二重結合を示す。] で表わされるカルボスチリル誘導体及びその塩。(1) General formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ [In the formula, R is a hydrogen atom, lower alkyl group, lower alkoxy group, group ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (R^3^
a and R^3^b are the same or different and represent a hydrogen atom or a lower alkyl group. Further, R^3^a and R^3^b may form a 5- to 6-membered saturated heterocycle with or without a nitrogen atom or an oxygen atom, together with the nitrogen atom to which they are bonded. ) or a halogen atom-substituted lower alkyl group. A is a group ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (R^2 is a hydroxyl group,
Indicates a lower alkoxy group or a lower alkanoyloxy group. ), the group -CH=CH-, or the group ▲Mathematical formulas, chemical formulas, tables, etc. are available▼. O represents 1 or 2. B represents a lower alkylene group. R^1 is a pyridyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group, and an amino group that may have a lower alkyl group as a substituent; Piperidinyl group, pyrazyl group, or group that may have a lower alkyl group as a substituent ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (R^3 and R^4
are the same or different and represent a hydrogen atom or a lower alkyl group. Further, R^3 and R^4 may form a 5- to 6-membered saturated heterocycle together with the nitrogen atom to which they are bonded, with or without a nitrogen or oxygen atom. The heterocycle may be substituted with a lower alkyl group as a substituent. ) is shown. l, m and n
indicates 0 or 1, respectively. However, l+m must not be 0. Furthermore, when A indicates ▲There are mathematical formulas, chemical formulas, tables, etc.▼, m is 1
shall be shown. The bonds at the 3rd and 4th positions of the carbostyryl skeleton represent a single bond or a double bond. ] A carbostyryl derivative represented by these and its salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5058489A JPH02229165A (en) | 1989-03-02 | 1989-03-02 | Carbostyril derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5058489A JPH02229165A (en) | 1989-03-02 | 1989-03-02 | Carbostyril derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02229165A true JPH02229165A (en) | 1990-09-11 |
Family
ID=12863026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5058489A Pending JPH02229165A (en) | 1989-03-02 | 1989-03-02 | Carbostyril derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02229165A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US7838527B2 (en) | 2002-11-13 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
| US8299081B2 (en) | 2005-05-13 | 2012-10-30 | Novartis Ag | Methods for treating drug resistant cancer |
-
1989
- 1989-03-02 JP JP5058489A patent/JPH02229165A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US7838527B2 (en) | 2002-11-13 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
| US8299081B2 (en) | 2005-05-13 | 2012-10-30 | Novartis Ag | Methods for treating drug resistant cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2199251T3 (en) | BENZOHETEROCICLIC DERIVATIVES USED AS VASOPRESIN OR OXITOCINE MODULATORS. | |
| AU680870B2 (en) | New heterocyclic compounds | |
| US5300513A (en) | Carbostyril derivatives and pharmaceutical composition containing the same | |
| JP2763036B2 (en) | Heterocyclic compounds | |
| US6235758B1 (en) | Indole derivatives as 5-HT receptor antagonist | |
| US5502065A (en) | Indole derivatives as 5-HT1 -like agonists | |
| EP0767170B1 (en) | Novel 4,6-diarylpyrimidine derivatives and salts thereof | |
| JP4845733B2 (en) | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxide as P38 kinase inhibitor | |
| DE60315479T2 (en) | PYRIMIDINAMIDE DERIVATIVES AND THEIR USE | |
| JPS63230687A (en) | Carbostyril derivative | |
| WO2001007411A1 (en) | Biarylurea derivatives | |
| WO1997028128A1 (en) | Heterocyclic compounds useful as pharmaceutical agents | |
| JPWO2002088112A1 (en) | Heterocyclic compound and antitumor agent containing the same as active ingredient | |
| RU2124017C1 (en) | Indane condensed derivatives, method of their synthesis and composition showing antitumor effect | |
| US5750699A (en) | Method of preparing certain 3-halo-imidazopyridines | |
| US5919811A (en) | 3-Substituted-indole-2-carboxylic acid derivatives as excitatory amino acid antagonists | |
| JP4108123B2 (en) | Tetrahydroquinoline as an NMDA antagonist | |
| CA1332835C (en) | Aliphatic carboxamides | |
| JPS6320226B2 (en) | ||
| WO1998042672A1 (en) | Benzene derivatives | |
| CN107810185A (en) | Bicyclic heterocycles derivative as bromine domain inhibitor | |
| JPH02289548A (en) | Pyridine compound | |
| JP2008543820A (en) | N- (2,2-dimethylpropyl) -6- (3-fluoro-5-((3-isoxazolylamino) carbonyl) -2-methylphenyl) -3-pyridinecarboxamide | |
| JPH02229165A (en) | Carbostyril derivative | |
| CN115785154B (en) | Heteroaromatic compounds and their medical uses |